

CPC**COOPERATIVE PATENT CLASSIFICATION****C12N****MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF**

(biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material [A01N 63/00](#); food compositions [A21](#), [A23](#); medicinal preparations [A61K](#); chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles [A61L](#); fertilisers [C05](#)); **PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS** (preservation of living parts of humans or animals [A01N 1/02](#)); **MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA** (micro-biological testing media [C12Q](#))

NOTES

1. Documents relating to the use of vectors or hosts for the preparation of specific peptides, e.g. enzymes, are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes.
2. Attention is drawn to Notes (1) to (3) following the title of Class [C12](#).
3. When classifying in this group, classification is also made in group [B01D 15/08](#) insofar as subject matter of general interest relating to chromatography is concerned.

WARNING

The following IPC groups are not used in the CPC scheme. Subject matter covered by these groups is classified in the following CPC groups:

[C12N 1/11](#) covered by [C12N 15/79](#)

[C12N 1/13](#) covered by [C12N 15/79](#)

[C12N 1/15](#) covered by [C12N 15/80](#)

[C12N 1/19](#) covered by [C12N 15/81](#)

[C12N 1/21](#) covered by [C12N 15/74](#)

[C12N 5/02](#) covered by [C12N 5/00](#), [C12N 5/04](#) to [C12N 5/166](#)

[C12N 5/07](#) - [C12N 5/095](#) covered by [C12N 5/06](#) and subgroups

[C12N 5/18](#) - [C12N 5/28](#) covered by [C12N 5/16](#) and subgroups

[C12N 5/18](#) covered by [C12N 5/16](#)

[C12N 5/20](#) covered by [C12N 5/163](#)

[C12N 5/22](#) covered by [C12N 5/16](#)

[C12N 5/24](#) covered by [C12N 5/163](#)

[C12N 5/26](#) covered by [C12N 5/166](#)

[C12N 5/28](#) covered by [C12N 5/166](#)

[C12N 7/01](#) covered by [C12N 7/00](#)

[C12N 9/26](#) covered by [C12N 9/2408](#)

[C12N 9/38](#) covered by [C12N 9/2468](#)

C12N

(continued)

C12N 9/42 covered by [C12N 9/2434](#)
C12N 9/44 covered by [C12N 9/2451](#)
C12N 9/70 covered by [C07K 14/3153](#)
C12N 15/05 covered by [C12N 5/14](#)
C12N 15/06 covered by [C12N 5/16](#)
C12N 15/07 covered by [C12N 5/16](#)
C12N 15/08 covered by [C12N 5/166](#)
C12N 15/12 covered by [C07K 14/435](#)
C12N 15/13 covered by [C07K 16/00](#)
C12N 15/14 covered by [C07K 14/765](#)
C12N 15/15 covered by [C07K 14/81](#)
C12N 15/16 covered by [C07K 14/575](#)
C12N 15/17 covered by [C07K 14/62](#)
C12N 15/18 covered by [C07K 14/61](#)
C12N 15/19 covered by [C07K 14/52](#)
C12N 15/20 covered by [C07K 14/555](#)
C12N 15/21 covered by [C07K 14/56](#)
C12N 15/22 covered by [C07K 14/565](#)
C12N 15/23 covered by [C07K 14/57](#)
C12N 15/24 covered by [C07K 14/54](#)
C12N 15/25 covered by [C07K 14/545](#)
C12N 15/26 covered by [C07K 14/55](#)
C12N 15/27 covered by [C07K 14/53](#)
C12N 15/28 covered by [C07K 14/525](#)
C12N 15/29 covered by [C07K 14/415](#)
C12N 15/30 covered by [C07K 14/44](#)
C12N 15/31 covered by [C07K 14/195](#), [C07K 14/005](#)
C12N 15/32 covered by [C07K 14/325](#)
C12N 15/33 covered by [C07K 14/005](#)
C12N 15/34 covered by [C07K 14/01](#)
C12N 15/35 covered by [C07K 14/015](#)
C12N 15/36 covered by [C07K 14/02](#)
C12N 15/37 covered by [C07K 14/025](#)
C12N 15/38 covered by [C07K 14/03](#)
C12N 15/39 covered by [C07K 14/065](#)
C12N 15/40 covered by [C07K 14/08](#)
C12N 15/41 covered by [C07K 14/085](#)
C12N 15/42 covered by [C07K 14/09](#)
C12N 15/43 covered by [C07K 14/105](#)
C12N 15/44 covered by [C07K 14/11](#)
C12N 15/45 covered by [C07K 14/115](#)
C12N 15/46 covered by [C07K 14/14](#)
C12N 15/47 covered by [C07K 14/145](#)
C12N 15/48 covered by [C07K 14/15](#)
C12N 15/49 covered by [C07K 14/155](#)

C12N

(continued)

[C12N 15/50](#) covered by [C07K 14/165](#)
[C12N 15/51](#) covered by [C07K 14/02](#), [C07K 14/10](#),
[C07K 14/18](#)
[C12N 15/53](#) covered by [C12N 9/02](#)
[C12N 15/54](#) covered by [C12N 9/10](#)
[C12N 15/55](#) covered by [C12N 9/14](#)
[C12N 15/56](#) covered by [C12N 9/24](#)
[C12N 15/57](#) covered by [C12N 9/48](#)
[C12N 15/58](#) covered by [C12N 9/6456](#)
[C12N 15/59](#) covered by [C12N 9/6483](#)
[C12N 15/60](#) covered by [C12N 9/88](#)
[C12N 15/61](#) covered by [C12N 9/90](#)
[C12N 15/83](#) covered by [C12N 15/82](#)
[C12N 15/84](#) covered by [C12N 15/82](#)

C12N 1/00

Micro-organisms, e.g. protozoa; Compositions thereof (medicinal preparations containing material from micro-organisms [A61K 35/66](#); preparing medicinal bacterial antigen or antibody compositions, e.g. bacterial vaccines [A61K 39/00](#)); **Processes of propagating, maintaining or preserving micro-organisms or compositions thereof; Processes of preparing or isolating a composition containing a micro-organism; Culture media therefor**

- [C12N 1/005](#) . {after treatment of microbial biomass not covered by [C12N 1/02](#) to [C12N 1/08](#)}
- [C12N 1/02](#) . Separating micro-organisms from their culture media
- [C12N 1/04](#) . Preserving or maintaining viable micro-organisms ([immobilised micro-organisms C12N 11/00](#))
- [C12N 1/06](#) . Lysis of micro-organisms
- [C12N 1/063](#) . . {of yeast}
- [C12N 1/066](#) . . {by physical methods}
- [C12N 1/08](#) . Reducing the nucleic acid content
- [C12N 1/10](#) . Protozoa; Culture media therefor
- [C12N 1/12](#) . Unicellular algae; Culture media therefor ([culture of multi-cellular plants A01G](#); as new plants [A01H 13/00](#))
- [C12N 1/14](#) . Fungi ([culture of mushrooms A01G 1/04](#); as new plants per se [A01H 15/00](#); {fungi per se [C12R 1/645](#) to [C12R 1/885](#)}) Culture media therefor
- [C12N 1/16](#) . . Yeasts; Culture media therefor
- [C12N 1/18](#) . . . Baker's yeast; Brewer's yeast
- [C12N 1/20](#) . Bacteria {(bacteria per se [C12R 1/01](#) to [C12R 1/64](#))}; Culture media therefor
- [C12N 1/22](#) . Processes using, or culture media containing, cellulose or hydrolysates thereof
- [C12N 1/24](#) . Processes using, or culture media containing, waste sulfite liquor
- [C12N 1/26](#) . Processes using, or culture media containing, hydrocarbons ([refining of hydrocarbon oils by using micro-organisms C10G 32/00](#))
- [C12N 1/28](#) . . aliphatic
- [C12N 1/30](#) . . . having five or less carbon atoms
- [C12N 1/32](#) . Processes using, or culture media containing, lower alkanols, i.e. C1 to C6

- C12N 1/34 . Processes using foam culture
- C12N 1/36 . Adaptation or attenuation of cells
- C12N 1/38 . Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound ([C12N 1/34](#) takes precedence)

C12N 3/00 Spore forming or isolating processes

C12N 5/00 Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques [A01H 4/00](#))

NOTE

In this group, the following words are used with the meanings indicated:

- a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta;
- a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);
- a "multipotent" cell is restricted to one lineage;
- "progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells. Unless provided for otherwise, committed progenitors are classified with their progeny.

- C12N 5/0006 . {Modification of the membrane of cells, e.g. cell decoration}
- C12N 5/0012 . {Cell encapsulation}
- C12N 5/0018 . {Culture media for cell or tissue culture (media for specific animal cell type [C12N 5/06](#))}
- C12N 5/0025 . . {Culture media for plant cell or plant tissue culture}
- C12N 5/0031 . . {Serum-free culture media}

WARNING

This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to [C12N 5/0037](#) to [C12N 5/0056](#)

- C12N 5/0037 . . {Serum-free medium, which may still contain naturally-sourced components}
- C12N 5/0043 . . {Medium free of human- or animal-derived components}
- C12N 5/005 . . {Protein-free medium}
- C12N 5/0056 . . {Xeno-free medium}
- C12N 5/0062 . {General methods for three-dimensional culture}
- C12N 5/0068 . {General culture methods using substrates (for specific animal cell type [C12N 5/06](#))}
- C12N 5/0075 . . {using microcarriers}
- C12N 5/0081 . {Purging biological preparations of unwanted cells}

- C12N 5/0087 . . {Purging against subsets of blood cells, e.g. purging alloreactive T cells}
- C12N 5/0093 . . {Purging against cancer cells}
- C12N 5/04 . Plant cells or tissues {(culture media [C12N 5/0025](#))}
- C12N 5/06 . Animal cells or tissues; {Human cells or tissues (preservation of living cells or tissues [A01N 1/02](#)); Not used, see subgroups}

NOTE

In this group, the following words are used with the meanings indicated:

- a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta;
- a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);
- a "multipotent" cell is restricted to one lineage.

"Progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells

- C12N 5/0601 . . {Invertebrate cells or tissues, e.g. insect cells; Culture media therefor}
- C12N 5/0602 . . {Vertebrate cells}

NOTE

Three-dimensional culture, tissue culture or organ culture are classified with the corresponding cells, if not specially provided for

- C12N 5/0603 . . . {Embryonic cells (production of embryos, nuclear transfer [A01K 67/027](#)); Embryoid bodies}
- C12N 5/0604 {Whole embryos; Culture medium therefor}
- C12N 5/0605 {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- C12N 5/0606 {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells [C12N 5/0611](#), induced pluripotent stem cells [C12N 5/0696](#))}
- C12N 5/0607 {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells [C12N 5/0696](#))}
- C12N 5/0608 {Germ cells (production of embryos, nuclear transfer [A01K 67/027](#)); Not used, see subgroups}
- C12N 5/0609 {Oocytes, oogonia (fertilised oocytes [C12N 5/0604](#))}
- C12N 5/061 {Sperm cells, spermatogonia}
- C12N 5/0611 {Primordial germ cells, e.g. embryonic germ cells [EG]}
- C12N 5/0612 {sorting of gametes, e.g. according to sex or motility}
- C12N 5/0613 {Cells from endocrine organs (pancreas [C12N 5/0676](#), gonads [C12N 5/0681](#))}
- C12N 5/0614 {Adrenal gland}
- C12N 5/0615 {Pineal gland}
- C12N 5/0616 {Pituitary gland}
- C12N 5/0617 {Thyroid and parathyroid glands}

C12N 5/0618	. . .	{Cells of the nervous system}
C12N 5/0619	{Neurons}
C12N 5/062	{Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain}
C12N 5/0621	{Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N 5/062)}
C12N 5/0622	{Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells}
C12N 5/0623	{Stem cells}
C12N 5/0625	. . .	{Epidermal cells, skin cells; Cells of the oral mucosa}
C12N 5/0626	{Melanocytes}
C12N 5/0627	{Hair cells}
C12N 5/0628	{Hair stem cells; Hair progenitors (mesenchymal stem cells from hair follicles C12N 5/0666)}
C12N 5/0629	{Keratinocytes; Whole skin}
C12N 5/063	{Keratinocyte stem cells; Keratinocyte progenitors}
C12N 5/0631	{Mammary cells}
C12N 5/0632	{Cells of the oral mucosa}
C12N 5/0633	{Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands}
C12N 5/0634	. . .	{Cells from the blood or the immune system}

NOTE

Committed progenitors are classified with their progeny

C12N 5/0635	{B lymphocytes}
C12N 5/0636	{T lymphocytes}
C12N 5/0637	{Immunosuppressive T lymphocytes, e.g. regulatory T cells (Treg)}
C12N 5/0638	{Cytotoxic T lymphocytes [CTL], lymphokine activated killer cells [LAK]}
C12N 5/0639	{Dendritic cells, e.g. Langerhans cells in the epidermis}
C12N 5/064	{Immunosuppressive dendritic cells}
C12N 5/0641	{Erythrocytes}
C12N 5/0642	{Granulocytes, e.g. basophils, eosinophils, neutrophils, mast cells}
C12N 5/0643	{Osteoclasts}
C12N 5/0644	{Platelets; Megakaryocytes}
C12N 5/0645	{Macrophages, e.g. Kuepfer cells in the liver; Monocytes}
C12N 5/0646	{Natural killers cells [NK], NKT cells}
C12N 5/0647	{Haematopoietic stem cells; Uncommitted or multipotent progenitors}
C12N 5/0648	{Splenocytes}
C12N 5/065	{Thymocytes}
C12N 5/0651	{Lymph nodes}
C12N 5/0652	. . .	{Cells of skeletal and connective tissues; Mesenchyme}
C12N 5/0653	{Adipocytes; Adipose tissue}

C12N 5/0654	{Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth}
C12N 5/0655	{Chondrocytes; Cartilage}
C12N 5/0656	{Adult fibroblasts}
C12N 5/0657	{Cardiomyocytes; Heart cells}
C12N 5/0658	{Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts}
C12N 5/0659 {Satellite cells}
C12N 5/066	{Tenocytes; Tendons, Ligaments}
C12N 5/0661	{Smooth muscle cells}
C12N 5/0662	{Stem cells}
C12N 5/0663 {Bone marrow mesenchymal stem cells (BM-MS)}
C12N 5/0664 {Dental pulp stem cells, Dental follicle stem cells}
C12N 5/0665 {Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood}
C12N 5/0666 {Mesenchymal stem cells from hair follicles}
C12N 5/0667 {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
C12N 5/0668 {Mesenchymal stem cells from other natural sources}
C12N 5/0669	{Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow C12N 5/0647 , C12N 5/0663)}
C12N 5/067	. . .	{Hepatocytes}
C12N 5/0671	{Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
C12N 5/0672	{Stem cells; Progenitor cells; Precursor cells; Oval cells}
C12N 5/0676	. . .	{Pancreatic cells}
C12N 5/0677	{Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
C12N 5/0678	{Stem cells; Progenitor cells; Precursor cells}
C12N 5/0679	. . .	{Cells of the gastro-intestinal tract}
C12N 5/068	{Stem cells; Progenitors}
C12N 5/0681	. . .	{Cells of the genital tract; Non-germinal cells from gonads; Not used, see subgroups}
C12N 5/0682	{Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N 5/0609)}
C12N 5/0683	{Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells (spermatogonia C12N 5/061)}
C12N 5/0684	. . .	{Cells of the urinary tract or kidneys}
C12N 5/0685	{Bladder epithelial cells}
C12N 5/0686	{Kidney cells}
C12N 5/0687	{Renal stem cells; Renal progenitors}
C12N 5/0688	. . .	{Cells from the lungs or the respiratory tract}
C12N 5/0689	{Stem cells; Progenitors}
C12N 5/069	. . .	{Vascular Endothelial cells}
C12N 5/0691	{Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels}

- C12N 5/0692 {Stem cells; Progenitor cells; Precursor cells}
- C12N 5/0693 {Tumour cells; Cancer cells}
- C12N 5/0694 {Cells of blood, e.g. leukemia cells, myeloma cells}
- C12N 5/0695 {Stem cells; Progenitor cells; Precursor cells}
- C12N 5/0696 {Artificially induced pluripotent stem cells, e.g. iPS}
- C12N 5/0697 . . {Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels [C12N 5/0691](#))}
- C12N 5/0698 {Skin equivalents}
- C12N 5/10 . Cells modified by introduction of foreign genetic material {Not used, see subgroups}
- C12N 5/12 . . Fused cells, e.g. hybridomas
- C12N 5/14 Plant cells
- C12N 5/16 Animal cells
- C12N 5/163 {one of the fusion partners being a B or a T lymphocyte}
- C12N 5/166 {resulting from interspecies fusion}

C12N 7/00 **Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof** (preparing medicinal viral antigen or antibody composition, e.g. virus vaccines, [A61K 39/00](#))

WARNING

From March 15, 2012 groups [C12N 7/02](#) - [C12N 7/08](#) and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range [C12N 2710/00-C12N 2795/00](#).

- C12N 7/02 . Recovery or purification
- C12N 7/025 . . {Packaging cell lines, e.g. transcomplementing cell lines, for production of virus}
- C12N 7/04 . Inactivation or attenuation; Producing viral sub-units
- C12N 7/045 . . {Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered}
- C12N 7/06 . . {Inactivation or attenuation} by chemical treatment
- C12N 7/08 . . {Inactivation or attenuation} by serial passage of virus

C12N 9/00 **Enzymes; Proenzymes; Compositions thereof** (preparations containing enzymes for cleaning teeth [A61K 8/66](#), [A61Q 11/00](#); medicinal preparations containing enzymes or pro-enzymes [A61K 38/43](#); enzyme containing detergent compositions [C11D](#); {enzymes with nucleic acid structure, e.g. ribozymes, [C12N 15/113](#)}); **Processes for preparing, activating, inhibiting, separating or purifying enzymes** (preparation of malt [C12C 1/00](#))

NOTE

Enzymes are generally categorized below according to the "Nomenclature and Classification of Enzymes" of the International Commission on Enzymes. Where appropriate, this designation appears in the groups below in parenthesis.

- C12N 9/0002 . {Antibodies with enzymatic activity; e.g. abzymes}

C12N 9/0004	. {Oxidoreductases (1.)}
C12N 9/0006	. . {acting on CH-OH groups as donors (1.1)}
C12N 9/0008	. . {acting on the aldehyde or oxo group of donors (1.2)}
C12N 9/001	. . {acting on the CH-CH group of donors (1.3)}
C12N 9/0012	. . {acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)}
C12N 9/0014	. . . {acting on the CH-NH ₂ group of donors (1.4)}
C12N 9/0016 {with NAD or NADP as acceptor (1.4.1)}
C12N 9/0018 {Phenylalanine dehydrogenase (1.4.1.20)}
C12N 9/002 {with a cytochrome as acceptor (1.4.2)}
C12N 9/0022 {with oxygen as acceptor (1.4.3)}
C12N 9/0024 {D-Amino acid oxidase (1.4.3.3)}
C12N 9/0026	. . . {acting on CH-NH groups of donors (1.5)}
C12N 9/0028 {with NAD or NADP as acceptor (1.5.1)}
C12N 9/003 {Dihydrofolate reductase [DHFR] (1.5.1.3)}
C12N 9/0032 {with oxygen as acceptor (1.5.3)}
C12N 9/0034 {Sarcosine oxidase (1.5.3.1)}
C12N 9/0036	. . . {acting on NADH or NADPH (1.6)}
C12N 9/0038 {with a heme protein as acceptor (1.6.2)}
C12N 9/004 {Cytochrome-b5 reductase (1.6.2.2)}
C12N 9/0042 {NADPH-cytochrome P450 reductase (1.6.2.4)}
C12N 9/0044	. . . {acting on other nitrogen compounds as donors (1.7)}
C12N 9/0046 {with oxygen as acceptor (1.7.3)}
C12N 9/0048 {Uricase (1.7.3.3)}
C12N 9/0051	. . {acting on a sulfur group of donors (1.8)}
C12N 9/0053	. . {acting on a heme group of donors (1.9)}
C12N 9/0055	. . {acting on diphenols and related substances as donors (1.10)}
C12N 9/0057	. . . {with oxygen as acceptor (1.10.3)}
C12N 9/0059 {Catechol oxidase (1.10.3.1), i.e. tyrosinase}
C12N 9/0061 {Laccase (1.10.3.2)}
C12N 9/0063 {Ascorbate oxidase (1.10.3.3)}
C12N 9/0065	. . {acting on hydrogen peroxide as acceptor (1.11)}
C12N 9/0067	. . {acting on hydrogen as donor (1.12)}
C12N 9/0069	. . {acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)}
C12N 9/0071	. . {acting on paired donors with incorporation of molecular oxygen (1.14)}
C12N 9/0073	. . . {with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13}
C12N 9/0075 {Nitric-oxide synthase (1.14.13.39)}
C12N 9/0077	. . . {with a reduced iron-sulfur protein as one donor (1.14.15)}
C12N 9/0079 {Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)}

C12N 9/0081 {Cholesterol monooxygenase (cytochrome P 450sc)(1.14.15.6)}
C12N 9/0083	. . . {Miscellaneous (1.14.99)}
C12N 9/0085 {Steroid 17 alpha-monooxygenase (1.14.99.9)}
C12N 9/0087 {Steroid 21-monooxygenase (1.14.99.10)}
C12N 9/0089	. . {acting on superoxide as acceptor (1.15)}
C12N 9/0091	. . {oxidizing metal ions (1.16)}
C12N 9/0093	. . {acting on CH or CH ₂ groups (1.17)}
C12N 9/0095	. . {acting on iron-sulfur proteins as donor (1.18)}
C12N 9/0097	. . {acting on reduced flavodoxin as donor (1.19)}
C12N 9/10	. Transferases (2.) (ribonucleases C12N 9/22)
C12N 9/1003	. . {transferring one-carbon groups (2.1)}
C12N 9/1007	. . . {Methyltransferases (general) (2.1.1.)}
C12N 9/1011 {Catechol O-methyltransferase (2.1.1.6)}
C12N 9/1014	. . . {Hydroxymethyl-, formyl-transferases (2.1.2)}
C12N 9/1018	. . . {Carboxy- and carbamoyl transferases (2.1.3)}
C12N 9/1022	. . {transferring aldehyde or ketonic groups (2.2)}
C12N 9/1025	. . {Acyltransferases (2.3)}
C12N 9/1029	. . . {transferring groups other than amino-acyl groups (2.3.1)}
C12N 9/1033 {Chloramphenicol O-acetyltransferase (2.3.1.28)}
C12N 9/1037 {Naringenin-chalcone synthase (2.3.1.74), i.e. chalcone synthase}
C12N 9/104	. . . {Aminoacyltransferases (2.3.2)}
C12N 9/1044 {Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII}
C12N 9/1048	. . {Glycosyltransferases (2.4)}
C12N 9/1051	. . . {Hexosyltransferases (2.4.1)}
C12N 9/1055 {Levansucrase (2.4.1.10)}
C12N 9/1059 {Cellulose synthases (2.4.1.12; 2.4.1.29)}
C12N 9/1062 {Sucrose synthase (2.4.1.13)}
C12N 9/1066 {Sucrose phosphate synthase (2.4.1.14)}
C12N 9/107 {1,4-Alpha-glucan branching enzyme (2.4.1.18)}
C12N 9/1074 {Cyclomalto-dextrin glucanotransferase (2.4.1.19)}
C12N 9/1077	. . . {Pentosyltransferases (2.4.2)}
C12N 9/1081	. . . {transferring other glycosyl groups (2.4.99)}
C12N 9/1085	. . {transferring alkyl or aryl groups other than methyl groups (2.5)}
C12N 9/1088	. . . {Glutathione transferase (2.5.1.18)}
C12N 9/1092	. . . {3-Phosphoshikimate 1-carboxyvinyltransferase (2.5.1.19), i.e. 5-enolpyruvylshikimate-3-phosphate synthase}
C12N 9/1096	. . {transferring nitrogenous groups (2.6)}
C12N 9/12	. . transferring phosphorus containing groups, e.g. kinases (2.7)
C12N 9/1205	. . . {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}

C12N 9/1211 {Thymidine kinase (2.7.1.21)}
C12N 9/1217	. . . {Phosphotransferases with a carboxyl group as acceptor (2.7.2)}
C12N 9/1223	. . . {Phosphotransferases with a nitrogenous group as acceptor (2.7.3)}
C12N 9/1229	. . . {Phosphotransferases with a phosphate group as acceptor (2.7.4)}
C12N 9/1235	. . . {Diphosphotransferases (2.7.6)}
C12N 9/1241	. . . {Nucleotidyltransferases (2.7.7)}
C12N 9/1247 {DNA-directed RNA polymerase (2.7.7.6)}
C12N 9/1252 {DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase}
C12N 9/1258 {Polyribonucleotide nucleotidyltransferase (2.7.7.8), i.e. polynucleotide phosphorylase}
C12N 9/1264 {DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase}
C12N 9/127 {RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase}
C12N 9/1276 {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}
C12N 9/1282 {RNA uridylyltransferase (2.7.7.52)}
C12N 9/1288	. . . {Transferases for other substituted phosphate groups (2.7.8)}
C12N 9/1294	. . . {Phosphotransferases with paired acceptors (2.7.9)}
C12N 9/13	. . {transferring sulfur containing groups (2.8)}
C12N 9/14	. Hydrolases (3)
C12N 9/16	. . acting on ester bonds (3.1)
C12N 9/18	. . . Carboxylic ester hydrolases {(3.1.1)}
C12N 9/20 Triglyceride splitting, e.g. by means of lipase
C12N 9/22	. . . Ribonucleases {RNAses, DNAses (catalytic nucleic acids C12N 15/113)}
C12N 9/24	. . acting on glycosyl compounds (3.2)
C12N 9/2402	. . . {hydrolysing O- and S- glycosyl compounds (3.2.1)}
C12N 9/2405 {Glucanases}
C12N 9/2408 {acting on alpha -1,4-glucosidic bonds}
C12N 9/2411 {Amylases}
C12N 9/2414 {Alpha-amylase (3.2.1.1.)}
C12N 9/2417 {from microbiological source}
C12N 9/242 {Fungal source}
C12N 9/2422 {from plant source}
C12N 9/2425 {Beta-amylase (3.2.1.2)}
C12N 9/2428 {Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase}
C12N 9/2431 {Beta-fructofuranosidase (3.2.1.26), i.e. invertase}
C12N 9/2434 {acting on beta-1,4-glucosidic bonds}
C12N 9/2437 {Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)}
C12N 9/244 {Endo-1,3(4)-beta-glucanase (3.2.1.6)}
C12N 9/2442 {Chitinase (3.2.1.14)}
C12N 9/2445 {Beta-glucosidase (3.2.1.21)}

C12N 9/2448	{Licheninase (3.2.1.73)}
C12N 9/2451	{acting on alpha-1,6-glucosidic bonds}
C12N 9/2454	{Dextranase (3.2.1.11)}
C12N 9/2457	{Pullulanase (3.2.1.41)}
C12N 9/246	{Isoamylase (3.2.1.68)}
C12N 9/2462	{Lysozyme (3.2.1.17)}
C12N 9/2465	{acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)}
C12N 9/2468	{acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)}
C12N 9/2471	{Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase}
C12N 9/2474	{Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase}
C12N 9/2477	{Hemicellulases not provided in a preceding group}
C12N 9/248	{Xylanases}
C12N 9/2482	{Endo-1,4-beta-xylanase (3.2.1.8)}
C12N 9/2485	{Xylan endo-1,3-beta-xylosidase (3.2.1.32), i.e. endo-1,3-beta-xylanase}
C12N 9/2488	{Mannanases}
C12N 9/2491	{Beta-mannosidase (3.2.1.25), i.e. mannanase}
C12N 9/2494	{Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase}
C12N 9/2497	{hydrolysing N- glycosyl compounds (3.2.2)}
C12N 9/48	acting on peptide bonds (3.4)
C12N 9/485	{Exopeptidases (3.4.11-3.4.19)}
C12N 9/50	Proteinases {Endopeptidases (3.4.21-3.4.25)}
C12N 9/503	{derived from viruses}
C12N 9/506	{derived from RNA viruses}
C12N 9/52	derived from bacteria
C12N 9/54	bacteria being Bacillus
C12N 9/58	derived from fungi
C12N 9/60	from yeast
C12N 9/62	from Aspergillus
C12N 9/63	{derived from plants}
C12N 9/64	derived from animal tissue
C12N 9/6402	{from non-mammals}
C12N 9/6405	{not being snakes}
C12N 9/6408	{Serine endopeptidases (3.4.21)}
C12N 9/641	{Cysteine endopeptidases (3.4.22)}
C12N 9/6413	{Aspartic endopeptidases (3.4.23)}
C12N 9/6416	{Metalloendopeptidases (3.4.24)}
C12N 9/6418	{from snakes}

C12N 9/6421	{from mammals}
C12N 9/6424	{Serine endopeptidases (3.4.21)}
C12N 9/6427	{Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)}
C12N 9/6429	{Thrombin (3.4.21.5)}
C12N 9/6432	{Coagulation factor Xa (3.4.21.6)}
C12N 9/6435	{Plasmin (3.4.21.7), i.e. fibrinolysin}
C12N 9/6437	{Coagulation factor VIIa (3.4.21.21)}
C12N 9/644	{Coagulation factor IXa (3.4.21.22)}
C12N 9/6443	{Coagulation factor XIa (3.4.21.27)}
C12N 9/6445	{Kallikreins (3.4.21.34; 3.4.21.35)}
C12N 9/6448	{Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37)}
C12N 9/6451	{Coagulation factor XIIa (3.4.21.38)}
C12N 9/6454	{Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases}
C12N 9/6456	{Plasminogen activators}
C12N 9/6459	{t-plasminogen activator (3.4.21.68), i.e. tPA}
C12N 9/6462	{u-Plasminogen activator (3.4.21.73), i.e. urokinase}
C12N 9/6464	{Protein C (3.4.21.69)}
C12N 9/6467	{Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)}
C12N 9/647	{Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups}
C12N 9/6472	{Cysteine endopeptidases (3.4.22)}
C12N 9/6475	{Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)}
C12N 9/6478	{Aspartic endopeptidases (3.4.23)}
C12N 9/6481	{Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)}
C12N 9/6483	{Chymosin (3.4.23.4), i.e. rennin}
C12N 9/6486	{Renin (3.4.23.15)}
C12N 9/6489	{Metalloendopeptidases (3.4.24)}
C12N 9/6491	{Matrix metalloproteases (MMP's), e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)}
C12N 9/6494	{Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11}
C12N 9/6497	{Endothelin-converting enzyme (3.4.24.71)}
C12N 9/78	. .	acting on carbon to nitrogen bonds other than peptide bonds (3.5)
C12N 9/80	. . .	acting on amide bonds in linear amides {(3.5.1)}
C12N 9/82	Asparaginase {(3.5.1.1)}
C12N 9/84	Penicillin amidase {(3.5.1.11)}
C12N 9/86	. . .	acting on amide bonds in cyclic amides, e.g. penicillinase {(3.5.2)}
C12N 9/88	. .	Lyases (4.)

- C12N 9/90 . Isomerases (5.)
- C12N 9/92 . . Glucose isomerase {(5.3.1.5; 5.3.1.9; 5.3.1.18)}
- C12N 9/93 . {Ligases (6)}
- C12N 9/94 . Pancreatin
- C12N 9/96 . Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C12N 9/98 . Preparation of granular or free-flowing enzyme compositions ([C12N 9/96 takes precedence](#))
- C12N 9/99 . Enzyme inactivation by chemical treatment

C12N 11/00 Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof

- C12N 11/02 . Enzymes or microbial cells being immobilised on or in an organic carrier
- C12N 11/04 . . entrapped within the carrier, e.g. gel, hollow fibre
- C12N 11/06 . . attached to the carrier via a bridging agent
- C12N 11/08 . . carrier being a synthetic polymer
- C12N 11/10 . . carrier being a carbohydrate
- C12N 11/12 . . . Cellulose or derivative thereof
- C12N 11/14 . Enzymes or microbial cells being immobilised on or in an inorganic carrier
- C12N 11/16 . Enzymes or microbial cells being immobilised on or in a biological cell
- C12N 11/18 . Multi-enzyme systems

C12N 13/00 Treatment of micro-organisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves

C12N 15/00 Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered micro-organisms, per se [C12N 1/00](#), [C12N 5/00](#), [C12N 7/00](#); new plants per se [A01H](#); plant reproduction by tissue culture techniques [A01H 4/00](#); new animals per se [A01K 67/00](#); use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy [A61K 48/00](#))

- C12N 15/01 . Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
- C12N 15/02 . Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion {(monoclonal antibodies [C07K 16/00](#); apparatus for cell fusion [C12M](#))}
- C12N 15/03 . . Bacteria
- C12N 15/04 . . Fungi
- C12N 15/09 . Recombinant DNA-technology
- C12N 15/10 . . Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA [C07H 21/00](#); preparation of non-structural polynucleotides from micro-organisms or with enzymes [C12P 19/34](#))

NOTE

C12N 15/10

(continued)

After the symbol [C12N 15/10](#) to [C12N 15/1096](#), and separated therefrom by a + sign, it is desirable to add the indexing codes selected from groups [C12Q 2500/00](#) to [C12Q 2565/634](#), relating to relevant technical features of the invention. When more than one indexing code is selected, the different codes are separated by a + sign. Example : [C12N 15/1037](#) + [C12Q 2537/125](#) + [C12Q 2521/537](#)

C12N 15/1003	. . .	{Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}
C12N 15/1006	{by means of a solid support carrier, e.g. particles, polymers}
C12N 15/101	{by chromatography, e.g. electrophoresis, ion-exchange, reverse phase}
C12N 15/1013	{by using magnetic beads}
C12N 15/1017	{by filtration, e.g. using filters, frits, membranes}
C12N 15/102	. . .	{Mutagenizing nucleic acids}
C12N 15/1024	{In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair}
C12N 15/1027	{by DNA shuffling, e.g. RSR, STEP, RPR}
C12N 15/1031	{mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR}
C12N 15/1034	. . .	{Isolating an individual clone by screening libraries}
C12N 15/1037	{Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
C12N 15/1041	{Ribosome/Polysome display, e.g. SPERT, ARM}
C12N 15/1044	{Preparation or screening of libraries displayed on scaffold proteins} s
C12N 15/1048	{SELEX}
C12N 15/1051	{Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors}
C12N 15/1055	{Protein x Protein interaction, e.g. two hybrid selection}
C12N 15/1058	{Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms}
C12N 15/1062	{mRNA-Display, e.g. polypeptide and encoding template are connected covalently}
C12N 15/1065	{Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags}
C12N 15/1068	{Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis}
C12N 15/1072	{Differential gene expression library synthesis, e.g. subtracted libraries, differential screening}
C12N 15/1075	{by coupling phenotype to genotype, not provided for in other groups of this subclass}
C12N 15/1079	{Screening libraries by altering the phenotype or phenotypic trait of the host (reporter assays C12N 15/1086)}

C12N 15/1082	{Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
C12N 15/1086	{Preparation or screening of expression libraries, e.g. reporter assays}
C12N 15/1089	{Design, preparation, screening or analysis of libraries using computer algorithms}
C12N 15/1093	{General methods of preparing gene libraries, not provided for in other subgroups}
C12N 15/1096	. . .	{cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR}
C12N 15/11	. .	DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H 21/00); {Non-coding nucleic acids having a biological activity}

NOTE

Documents relating to DNA or its corresponding RNA and their use in recombinant DNA technology or the preparation of specific peptides, e.g. enzymes, are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes relating to their use in recombinant technology. Groups [C12N 15/11](#) to [C12N 15/117](#) cover also the use of non-coding nucleic acids as active ingredients in medicinal preparations. The [C12N 2303/00](#) ICO scheme has to be applied to these groups. When documents classifiable in one or more subgroups disclose general principles of the technology applicable to the whole field, classification is also made in group [C12N 15/111](#)

C12N 15/111	. . .	{General methods applicable to biologically active non-coding nucleic acids}
C12N 15/113	. . .	Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N 15/8218)}
C12N 15/1131	{against viruses}
C12N 15/1132	{against retroviridae, e.g. HIV}
C12N 15/1133	{against herpesviridae, e.g. HSV}
C12N 15/1135	{against oncogenes or tumor suppressor genes}
C12N 15/1136	{against growth factors, growth regulators, cytokines, lymphokines or hormones}
C12N 15/1137	{against enzymes (viral enzymes C12N 15/1131 ; receptors C12N 15/1138)}
C12N 15/1138	{against receptors or cell surface proteins}
C12N 15/115	. . .	Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith; {Nucleic acids binding to non-nucleic acids, e.g. aptamers}

NOTE

Aptamers fused to compounds which are already classified in groups [C12N 15/11](#) to [C12N 15/117](#), are classified with the corresponding compound

- C12N 15/117 . . . Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- C12N 15/52 . . . Genes encoding for enzymes or proenzymes

NOTE

In this group genes encoding for proenzymes are classified with the corresponding genes encoding enzymes.

- C12N 15/62 . . . DNA sequences coding for fusion proteins

NOTE

In this group, the following term is used with the meaning indicated:

- "fusion" means the fusion of two different proteins.

- C12N 15/625 {containing a sequence coding for a signal sequence}
- C12N 15/63 . . . Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 15/635 . . . {Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracycline}
- C12N 15/64 . . . General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
- C12N 15/65 . . . using markers (enzymes used as markers [C12N 15/52](#))
- C12N 15/66 . . . General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

NOTE

In this group, the following expression is used with the meaning indicated:

- "non-functional linkers" means DNA sequences which are used to link DNA sequences and which have no known function of structural gene or regulating function.

- C12N 15/67 . . . General methods for enhancing the expression
- C12N 15/68 Stabilisation of the vector
- C12N 15/69 Increasing the copy number of the vector
- C12N 15/70 . . . Vectors or expression systems specially adapted for E. coli

NOTES

1. This group covers the use of E. coli as host.
2. Shuttle vectors also replicating in E. coli are classified according to the other host.

- C12N 15/71 Expression systems using regulatory sequences derived from the trp-operon
- C12N 15/72 Expression systems using regulatory sequences derived from the lac-operon
- C12N 15/73 Expression systems using phage (lambda) regulatory sequences

- C12N 15/74 . . . Vectors or expression systems specially adapted for prokaryotic hosts other than *E. coli*, e.g. *Lactobacillus*, *Micromonospora*

NOTE

This group covers the use of prokaryotes as hosts.

- C12N 15/743 {for *Agrobacterium*; *Rhizobium*; *Bradyrhizobium*}
- C12N 15/746 {for lactic acid bacteria (*Streptococcus*; *Lactococcus*; *Lactobacillus*; *Pediococcus*; *Enterococcus*; *Leuconostoc*; *Propionibacterium*; *Bifidobacterium*; *Sporolactobacillus*)}
- C12N 15/75 for *Bacillus*
- C12N 15/76 for *Actinomyces*; for *Streptomyces*
- C12N 15/77 for *Corynebacterium*; for *Brevibacterium*
- C12N 15/78 for *Pseudomonas*
- C12N 15/79 . . . Vectors or expression systems specially adapted for eukaryotic hosts

NOTE

This group covers the use of eukaryotes as hosts.

- C12N 15/80 for fungi
- C12N 15/81 for yeasts
- C12N 15/815 {for yeasts other than *Saccharomyces*}
- C12N 15/82 for plant cells, {e.g. plant artificial chromosomes (PACs)}

WARNING

Documents are being continuously reclassified into this new classification scheme. See Warning notes below

- C12N 15/8201 {Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation}
- C12N 15/8202 {by biological means, e.g. cell mediated or natural vector}
- C12N 15/8203 {Virus mediated transformation}
- C12N 15/8205 {*Agrobacterium* mediated transformation}
- C12N 15/8206 {by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated}
- C12N 15/8207 {by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers}
- C12N 15/8209 {Selection, visualisation of transformants, reporter constructs, e.g. antibiotic resistance markers}

NOTE

Standard selectable markers such as neomycin phosphotransferase (NPT) are not systematically classified in [C12N 15/8209](#)

C12N 15/821	{Non-antibiotic resistance markers, e.g. morphogenetic, metabolic markers}
C12N 15/8212	{Colour markers, e.g. beta-glucuronidase [GUS], green fluorescent protein [GFP], carotenoid}
C12N 15/8213	{Targeted insertion of genes into the plant genome by homologous recombination}
C12N 15/8214	{Plastid transformation}
C12N 15/8216	{Methods for controlling, regulating or enhancing expression of transgenes in plant cells}
C12N 15/8217	{Gene switch}
C12N 15/8218	{Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]}
C12N 15/822	{Reducing position variability, e.g. by the use of scaffold attachment region/matrix attachment region (SAR/MAR); Use of SAR/MAR to regulate gene expression}
C12N 15/8221	{Transit peptides}
C12N 15/8222	{Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation}
C12N 15/8223	{Vegetative tissue-specific promoters}
C12N 15/8225	{Leaf-specific, e.g. including petioles, stomata}
C12N 15/8226	{Stem-specific, e.g. including tubers, beets}
C12N 15/8227	{Root-specific}
C12N 15/8229	{Meristem-specific, e.g. nodal, apical}
C12N 15/823	{Reproductive tissue-specific promoters}
C12N 15/8231	{Male-specific, e.g. anther, tapetum, pollen}
C12N 15/8233	{Female-specific, e.g. pistil, ovule}
C12N 15/8234	{Seed-specific, e.g. embryo, endosperm}
C12N 15/8235	{Fruit-specific}
C12N 15/8237	{Externally regulated expression systems}
C12N 15/8238	{chemically inducible, e.g. tetracycline}
C12N 15/8239	{pathogen inducible}
C12N 15/8241	{Phenotypically and genetically modified plants via recombinant DNA technology}
C12N 15/8242	{with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits}
C12N 15/8243	{involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine}
C12N 15/8245	{involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis}
C12N 15/8246	{Non-starch polysaccharides, e.g. cellulose, fructans, levans}
C12N 15/8247	{involving modified lipid metabolism, e.g. seed oil composition}
C12N 15/8249	{involving ethylene biosynthesis, senescence or fruit development, e.g. modified tomato ripening, cut flower shelf-life}

C12N 15/825 {involving pigment biosynthesis}

NOTE

Transgenic plants with altered flower morphology are also classified in this group

C12N 15/8251 {Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis}

C12N 15/8253 {Methionine or cysteine}

C12N 15/8254 {Tryptophan or lysine}

C12N 15/8255 {involving lignin biosynthesis}

C12N 15/8257 {for the production of primary gene products, e.g. pharmaceutical products, interferon}

C12N 15/8258 {for the production of oral vaccines (antigens) or immunoglobulins}

C12N 15/8259 {Phytoremediation}

C12N 15/8261 {with agronomic (input) traits, e.g. crop yield}

C12N 15/8262 {involving plant development (not used)}

C12N 15/8263 {Ablation; Apoptosis}

C12N 15/8265 {Transgene containment, e.g. gene dispersal}

C12N 15/8266 {Abscission; Dehiscence; Senescence}

C12N 15/8267 {Seed dormancy, germination or sprouting}

C12N 15/8269 {Photosynthesis}

C12N 15/827 {Flower development or morphology, e.g. flowering promoting factor [FPF]}

C12N 15/8271 {for stress resistance, e.g. heavy metal resistance}

C12N 15/8273 {for drought, cold, salt resistance}

C12N 15/8274 {for herbicide resistance}

C12N 15/8275 {Glyphosate}

C12N 15/8277 {Phosphinotricin}

C12N 15/8278 {Sulfonylurea}

C12N 15/8279 {for biotic stress resistance, pathogen resistance, disease resistance}

C12N 15/8281 {for bacterial resistance}

C12N 15/8282 {for fungal resistance}

C12N 15/8283 {for virus resistance}

C12N 15/8285 {for nematode resistance}

C12N 15/8286 {for insect resistance}

C12N 15/8287 {for fertility modification, e.g. apomixis}

C12N 15/8289 {Male sterility}

C12N 15/829 {Female sterility}

C12N 15/8291 {Hormone-influenced development}

C12N 15/8293	{Absciscic acid [ABA]}
C12N 15/8294	{Auxins}
C12N 15/8295	{Cytokinins}
C12N 15/8297	{Gibberellins; GA3}
C12N 15/8298	{Brassinosteroids}
C12N 15/85	for animal cells
C12N 15/8509	{for producing genetically modified animals, e.g. transgenic}

NOTE

The purpose of the modified animal is indicated using the codes under [A01K 2267/00](#)

C12N 2015/8518	{expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}
C12N 2015/8527	{for producing animal models, e.g. for tests or diseases}
C12N 2015/8536	{Animal models for genetic diseases}
C12N 2015/8545	{for Alzheimer's disease}
C12N 2015/8554	{Invertebrates models for Alzheimer's disease}
C12N 2015/8563	{for autoimmune diseases, e.g. Insulin-dependent diabetes mellitus}
C12N 2015/8572	{Animal models for proliferative diseases, e.g. comprising an oncogene}
C12N 2015/8581	{Animal models for infectious diseases, e.g. AIDS}
C12N 2015/859	{Animal models comprising reporter system for screening tests}
C12N 15/86	Viral vectors

WARNING

From March 15, 2012 groups [C12N 15/861](#) - [C12N 15/869](#) and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range [C12N 2710/00-C12N 2795/00](#)

C12N 15/861	Adenoviral vectors
C12N 15/8613	{Chimaeric vector systems comprising heterologous sequences for production of another viral vector}
C12N 15/8616	{Special methods for targeting systems}
C12N 15/863	Poxviral vectors, {e.g. entomopoxvirus}
C12N 15/8633	{Avian poxviral vectors}
C12N 15/8636	{Vaccina virus vectors}
C12N 15/864	Parvoviral vectors, {e.g. parvovirus, densovirus}
C12N 15/8645	{Adeno-associated virus}
C12N 15/866	Baculoviral vectors
C12N 15/867	Retroviral vectors

C12N 15/8673 {Special methods for packaging systems}
C12N 15/8676 {Special methods for targeting systems}
C12N 15/869 Herpesviral vectors
C12N 15/8695 {Herpes simplex virus-based vectors}
C12N 15/87	. . Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
C12N 15/873	. . . Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
C12N 15/877 Techniques for producing new mammalian cloned embryos
C12N 15/8771 {Bovine embryos}
C12N 15/8772 {Caprine embryos}
C12N 15/8773 {Ovine embryos}
C12N 15/8775 {Murine embryos}
C12N 15/8776 {Primate embryos}
C12N 15/8777 {Rabbit embryos}
C12N 15/8778 {Swine embryos}
C12N 15/88	. . . using micro-encapsulation, e.g. using {amphiphile} liposome vesicle
C12N 15/89	. . . using micro-injection
C12N 15/895 {using biolistic methods}
C12N 15/90	. . . Stable introduction of foreign DNA into chromosome
C12N 15/902 {using homologous recombination}
C12N 15/905 {in yeasts}
C12N 15/907 {in mammalian cells}

C12N 2303/00 **Indexing codes associated with general methodologies in the field of biologically active non-coding nucleic acids**

NOTE

Indexing codes of group [C12N 2303/00](#) are only used in combination with group [C12N 15/111](#)

C12N 2310/00	Structure or type of the nucleic acid
C12N 2310/10	. Type of nucleic acid
C12N 2310/11	. . Antisense
C12N 2310/111	. . . spanning the whole gene, or a large part of it
C12N 2310/113	. . . targeting other non-coding nucleic acids, e.g. antagomirs
C12N 2310/12	. . catalytic nucleic acids, e.g. ribozymes
C12N 2310/121	. . . Hammerhead
C12N 2310/122	. . . Hairpin
C12N 2310/123	. . . Hepatitis delta
C12N 2310/124	. . . based on group I or II introns

C12N 2310/1241 Tetrahymena
C12N 2310/126	. . . involving RNase P
C12N 2310/127	. . . DNAzymes
C12N 2310/128	. . . processing or releasing ribozyme
C12N 2310/13	. . Decoys
C12N 2310/14	. . interfering N.A.
C12N 2310/141	. . . MicroRNAs, miRNAs
C12N 2310/15	. . Nucleic acids forming more than 2 strands, e.g. TFOs
C12N 2310/151	. . . more than 3 strands, e.g. tetrads, H-DNA
C12N 2310/152	. . . on a single-stranded target, e.g. fold-back TFOs
C12N 2310/153	. . . with the aid of a protein, e.g. recombinase
C12N 2310/16	. . Aptamers
C12N 2310/17	. . Immunomodulatory nucleic acids
C12N 2310/18	. . acting by a non-sequence specific mechanism (other than C12N 2310/16 or C12N 2310/17)
C12N 2310/30	. Chemical structure
C12N 2310/31	. . of the backbone
C12N 2310/311	. . . Phosphotriesters
C12N 2310/312	. . . Phosphonates
C12N 2310/3125 Methylphosphonates
C12N 2310/313	. . . Phosphorodithioates
C12N 2310/314	. . . Phosphoramidates
C12N 2310/3145 with the nitrogen in 3' or 5'-position
C12N 2310/315	. . . Phosphorothioates
C12N 2310/316	. . . Phosphonothioates
C12N 2310/317	. . . with an inverted bond, e.g. a cap structure
C12N 2310/318	. . . where the PO ₂ is completely replaced, e.g. MMI or formacetal
C12N 2310/3181 Peptide nucleic acid, PNA
C12N 2310/3183 Diol linkers, e.g. glycols or propanediols
C12N 2310/319	. . . linked by 2'-5' linkages, i.e. having a free 3'-position
C12N 2310/32	. . of the sugar
C12N 2310/321	. . . 2'-O-R Modification
C12N 2310/322	. . . 2'-R Modification
C12N 2310/323	. . . modified ring structure
C12N 2310/3231 having an additional ring, e.g. LNA, ENA
C12N 2310/3233 Morpholino-type ring
C12N 2310/3235 having the O of the ribose replaced by another atom
C12N 2310/33	. . of the base
C12N 2310/331	. . . Universal or degenerate base
C12N 2310/332	. . . Abasic residue

C12N 2310/333	. . . Modified A
C12N 2310/334	. . . Modified C
C12N 2310/3341 5-Methylcytosine
C12N 2310/335	. . . Modified T or U
C12N 2310/336	. . . Modified G
C12N 2310/337	. . . in alpha-anomeric form
C12N 2310/34	. . Spatial arrangement of the modifications
C12N 2310/341	. . . Gapmers, i.e. of the type ===-=====
C12N 2310/342	. . . Hemimers, i.e. of the type =====
C12N 2310/343	. . . having patterns, e.g. =====
C12N 2310/344	. . . Position-specific modifications, e.g. on every purine, at the 3'-end
C12N 2310/345	. . . having at least two different backbone modifications
C12N 2310/346	. . . having a combination of backbone and sugar modifications
C12N 2310/35	. . Nature of the modification
C12N 2310/351	. . . Conjugate
C12N 2310/3511 intercalating or cleaving agent
C12N 2310/3513 Protein; Peptide
C12N 2310/3515 Lipophilic moiety, e.g. cholesterol
C12N 2310/3517 Marker; Tag
C12N 2310/3519 Fusion with another nucleic acid
C12N 2310/352	. . . linked to the nucleic acid via a carbon atom
C12N 2310/3521 Methyl
C12N 2310/3523 Allyl
C12N 2310/3525 MOE, methoxyethoxy
C12N 2310/3527 Other alkyl chain
C12N 2310/3529 Aromatic substituent
C12N 2310/353	. . . linked to the nucleic acid via an atom other than carbon
C12N 2310/3531	. . . Hydrogen
C12N 2310/3533	. . . Halogen
C12N 2310/3535	. . . Nitrogen
C12N 2310/50	. Physical structure
C12N 2310/51	. . in polymeric form, e.g. multimers, concatemers
C12N 2310/52	. . branched
C12N 2310/53	. . partially self-complementary or closed
C12N 2310/531	. . . Stem-loop; Hairpin
C12N 2310/532	. . . Closed or circular
C12N 2310/533	. . . having a mismatch or nick in at least one of the strands
C12N 2320/00	Applications; Uses
C12N 2320/10	. in screening processes

- C12N 2320/11 . . for the determination of target sites, i.e. of active nucleic acids
- C12N 2320/12 . . in functional genomics, i.e. for the determination of gene function
- C12N 2320/13 . . in a process of directed evolution, e.g. SELEX, acquiring a new function
- C12N 2320/30 . Special therapeutic applications
- C12N 2320/31 . . Combination therapy
- C12N 2320/32 . . Special delivery means, e.g. tissue-specific
- C12N 2320/33 . . Alteration of splicing
- C12N 2320/34 . . Allele or polymorphism specific uses
- C12N 2320/35 . . based on a specific dosage / administration regimen
- C12N 2320/50 . Methods for regulating/modulating their activity
- C12N 2320/51 . . modulating the chemical stability, e.g. nuclease-resistance
- C12N 2320/52 . . modulating the physical stability, e.g. GC-content
- C12N 2320/53 . . reducing unwanted side-effects

C12N 2330/00**Production**

- C12N 2330/10 . naturally occurring
- C12N 2330/30 . chemically synthesised
- C12N 2330/31 . . Libraries, arrays
- C12N 2330/50 . Biochemical production, i.e. in a transformed host cell
- C12N 2330/51 . . Specially adapted vectors

C12N 2500/00**Specific components of cell culture medium**

- C12N 2500/02 . Atmosphere, e.g. low oxygen conditions
- C12N 2500/05 . Inorganic components
- C12N 2500/10 . . Metals; Metal chelators ([cobalamine C12N 2500/38](#))
- C12N 2500/12 . . . Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N 2500/14 Calcium; Ca chelators; Calcitonin
- C12N 2500/16 Magnesium; Mg chelators
- C12N 2500/20 . . . Transition metals
- C12N 2500/22 Zinc; Zn chelators ([insulin-zinc complexes C12N 2501/33](#))
- C12N 2500/24 Iron; Fe chelators; Transferrin
- C12N 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
- C12N 2500/30 . Organic components ([metal chelators C12N 2500/10](#); [calcitonin C12N 2500/14](#); [transferrin C12N 2500/24](#))
- C12N 2500/32 . . Amino acids
- C12N 2500/33 . . . other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
- C12N 2500/34 . . Sugars
- C12N 2500/35 . . Polyols, e.g. glycerin, inositol
- C12N 2500/36 . . Lipids
- C12N 2500/38 . . Vitamins

- C12N 2500/40 . . Nucleotides, nucleosides, bases ([cyclic nucleotides C12N 2501/01](#), [anti-neoplastic drugs C12N 2501/06](#))
- C12N 2500/42 . . Organic phosphate, e.g. beta glycerophosphate
- C12N 2500/44 . . Thiols, e.g. mercaptoethanol
- C12N 2500/46 . . Amines, e.g. putrescine
- C12N 2500/50 . Soluble polymers, e.g. polyethyleneglycol [PEG]
- C12N 2500/60 . Buffer, e.g. pH regulation, osmotic pressure
- C12N 2500/62 . . DMSO
- C12N 2500/70 . Undefined extracts ([conditioned medium C12N 2502/00](#))
- C12N 2500/72 . . from bacteria
- C12N 2500/74 . . from fungi, e.g. yeasts
- C12N 2500/76 . . from plants
- C12N 2500/78 . . from protozoa
- C12N 2500/80 . . from animals
- C12N 2500/82 . . . from invertebrates
- C12N 2500/84 . . . from mammals
- C12N 2500/90 . Serum-free medium, which may still contain naturally-sourced components
- C12N 2500/92 . . Medium free of human- or animal-derived components
- C12N 2500/95 . . Protein-free medium and culture conditions
- C12N 2500/98 . Xeno-free medium and culture conditions
- C12N 2500/99 . Serum-free medium

WARNING

This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to [C12N 2500/90](#) to [C12N 2500/98](#)

C12N 2501/00 Active agents used in cell culture processes, e.g. differentiation**NOTE**

Whenever possible, indexation is done by signalling pathway and not by chemical structure, e.g. the group of a protein covers not only peptide analogs of it and the corresponding nucleic acids, as in [C07K 14/00](#), but also antibodies, anti-idiotypic antibodies, non-peptide ligands of the receptor, the receptor itself, antibodies against the receptor or inhibitors of the conversion enzyme which processes the protein precursor. Unless otherwise provided for, ligands and substrates take precedence over receptors and enzymes.

- C12N 2501/01 . Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- C12N 2501/02 . Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
- C12N 2501/03 . Compounds acting on the NO pathway, e.g. nitrososarginine
- C12N 2501/04 . Immunosuppressors, e.g. cyclosporin, tacrolimus

C12N 2501/05	. Adjuvants
C12N 2501/051	. . Lipid A (MPA, MPL)
C12N 2501/052	. . Lipopolysaccharides [LPS]
C12N 2501/054	. . Muramyle peptides
C12N 2501/056	. . Immunostimulating oligonucleotides, e.g. CpG
C12N 2501/06	. Anti-neoplastic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
C12N 2501/065	. Modulators of histone acetylation
C12N 2501/07	. Heat shock proteins
C12N 2501/10	. Growth factors
C12N 2501/105	. . Insulin-like growth factors [IGF]
C12N 2501/11	. . Epidermal growth factor [EGF]
C12N 2501/113	. . Acidic fibroblast growth factor (aFGF, FGF-1)
C12N 2501/115	. . Basic fibroblast growth factor (bFGF, FGF-2)
C12N 2501/117	. . Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
C12N 2501/119	. . Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
C12N 2501/12	. . Hepatocyte growth factor [HGF]
C12N 2501/125	. . Stem cell factor [SCF], c-kit ligand [KL]
C12N 2501/13	. . Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
C12N 2501/135	. . Platelet-derived growth factor [PDGF]
C12N 2501/14	. . Erythropoietin [EPO]
C12N 2501/145	. . Thrombopoietin [TPO]
C12N 2501/148	. . Transforming growth factor alpha [TGF- α]
C12N 2501/15	. . Transforming growth factor beta (TGF-?)
C12N 2501/155	. . Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
C12N 2501/16	. . Activin; Inhibin; Mullerian inhibiting substance
C12N 2501/165	. . Vascular endothelial growth factor [VEGF]
C12N 2501/17	. . Angiopoietin
C12N 2501/175	. . Cardiotrophin
C12N 2501/18	. . Liver cell growth factor (LCGF, Gly-His-Lys)
C12N 2501/185	. . Osteoprotegerin; Osteoclast differentiation factor (ODF, RANKL)
C12N 2501/19	. . Growth and differentiation factors [GDF]
C12N 2501/195	. . Heregulin, neu differentiation factor
C12N 2501/20	. Cytokines; Chemokines
C12N 2501/21	. . Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
C12N 2501/22	. . Colony stimulating factors (G-CSF, GM-CSF)
C12N 2501/23	. . Interleukins [IL]
C12N 2501/2301	. . . Interleukin-1 (IL-1)
C12N 2501/2302	. . . Interleukin-2 (IL-2)

C12N 2501/2303	. . .	Interleukin-3 (IL-3)
C12N 2501/2304	. . .	Interleukin-4 (IL-4)
C12N 2501/2305	. . .	Interleukin-5 (IL-5)
C12N 2501/2306	. . .	Interleukin-6 (IL-6)
C12N 2501/2307	. . .	Interleukin-7 (IL-7)
C12N 2501/2308	. . .	Interleukin-8 (IL-8)
C12N 2501/2309	. . .	Interleukin-9 (IL-9)
C12N 2501/231	. . .	Interleukin-10 (IL-10)
C12N 2501/2311	. . .	Interleukin-11 (IL-11)
C12N 2501/2312	. . .	Interleukin-12 (IL-12)
C12N 2501/2313	. . .	Interleukin-13 (IL-13)
C12N 2501/2314	. . .	Interleukin-14 (IL-14)
C12N 2501/2315	. . .	Interleukin-15 (IL-15)
C12N 2501/2316	. . .	Interleukin-16 (IL-16)
C12N 2501/2317	. . .	Interleukin-17 (IL-17)
C12N 2501/2318	. . .	Interleukin-18 (IL-18)
C12N 2501/2319	. . .	Interleukin-19 (IL-19)
C12N 2501/232	. . .	Interleukin-20 (IL-20)
C12N 2501/2321	. . .	Interleukin-21 (IL-21)
C12N 2501/2322	. . .	Interleukin-22 (IL-22)
C12N 2501/2323	. . .	Interleukin-23 (IL-23)
C12N 2501/2324	. . .	Interleukin-24 (IL-24)
C12N 2501/2325	. . .	Interleukin-25 (IL-25)
C12N 2501/2326	. . .	Interleukin-26 (IL-26)
C12N 2501/2327	. . .	Interleukin-27 (IL-27)
C12N 2501/2328	. . .	Interleukin-28 (IL-28)
C12N 2501/2329	. . .	Interleukin-29 (IL-29)
C12N 2501/233	. . .	Interleukin-30 (IL-30)
C12N 2501/2331	. . .	Interleukin-31 (IL-31)
C12N 2501/2332	. . .	Interleukin-32 (IL-32)
C12N 2501/2333	. . .	Interleukin-33 (IL-33)
C12N 2501/2334	. . .	Interleukin-34 (IL-34)
C12N 2501/2335	. . .	Interleukin-35 (IL-35)
C12N 2501/235	. . .	Leukemia inhibitory factor [LIF]
C12N 2501/237	. . .	Oncostatin M [OSM]
C12N 2501/24	. . .	Interferons [IFN]
C12N 2501/25	. . .	Tumour necrosing factors [TNF]
C12N 2501/26	. . .	Flt-3 ligand (CD135L, flk-2 ligand)
C12N 2501/30	. . .	Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C12N 2501/85)

C12N 2501/305	. . Growth hormone [GH], aka. somatotropin
C12N 2501/31	. . Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins
C12N 2501/315	. . Prolactin
C12N 2501/32	. . Angiotensins [AT], angiotensinogen
C12N 2501/33	. . Insulin (together with transferrin C12N 2500/25; Insulin-like growth factors C12N 2501/105)
C12N 2501/335	. . Glucagon; Glucagon-like peptide [GLP]; Exendin
C12N 2501/34	. . Calcitonin; Calcitonin-gene related peptide [CGRO]; Amylin
C12N 2501/345	. . Gastrin; Cholecystokinins [CCK]
C12N 2501/35	. . Vasoactive intestinal peptide [VIP]; Pituitary adenylate cyclase activating polypeptide [PACAP]
C12N 2501/355	. . Leptin
C12N 2501/36	. . Somatostatin
C12N 2501/365	. . Endothelin
C12N 2501/37	. . Parathyroid hormone [PTH]
C12N 2501/375	. . Thyroid stimulating hormone [TSH]
C12N 2501/38	. . with nuclear receptors
C12N 2501/385	. . . of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
C12N 2501/39	. . . Steroid hormones
C12N 2501/392 Sexual steroids
C12N 2501/395	. . . Thyroid hormones
C12N 2501/40	. Regulators of development
C12N 2501/405	. . Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
C12N 2501/41	. . Hedgehog proteins; Cyclopamine (inhibitor)
C12N 2501/415	. . Wnt; Frizzled
C12N 2501/42	. . Notch; Delta; Jagged; Serrate
C12N 2501/48	. . Regulators of apoptosis
C12N 2501/50	. Cell markers; Cell surface determinants
C12N 2501/505	. . CD4; CD8
C12N 2501/51	. . B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
C12N 2501/515	. . CD3, T-cell receptor complex
C12N 2501/52	. . CD40, CD40-ligand (CD154)
C12N 2501/53	. . CD2
C12N 2501/58	. . Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
C12N 2501/585	. . Integrins
C12N 2501/59	. . Lectins
C12N 2501/599	. . with CD designations not provided for elsewhere
C12N 2501/60	. Transcription factors

C12N 2501/602	. . Sox-2
C12N 2501/603	. . Oct-3/4
C12N 2501/604	. . Klf-4
C12N 2501/605	. . Nanog
C12N 2501/606	. . c-Myc
C12N 2501/608	. . Lin28
C12N 2501/65	. Micro-RNA
C12N 2501/70	. Enzymes
C12N 2501/71	. . Oxidoreductases (EC 1.)
C12N 2501/72	. . Transferases (EC 2.) (acetylation of histones C12N 2501/065)
C12N 2501/724	. . . Glycosyltransferases (EC 2.4.)
C12N 2501/727	. . . Kinases (EC 2.7.)
C12N 2501/73	. . Hydrolases (EC 3.)
C12N 2501/734	. . . Proteases (EC 3.4.)
C12N 2501/80	. Neurotransmitters; Neurohormones
C12N 2501/805	. . Acetylcholine
C12N 2501/81	. . Adrenaline
C12N 2501/815	. . Dopamine
C12N 2501/82	. . Histamine
C12N 2501/825	. . Serotonine (5-HT); Melatonine
C12N 2501/83	. . Tachykinins, e.g. substance P
C12N 2501/835	. . Neuropeptide Y [NPY]; Peptide YY [PYY]
C12N 2501/84	. . Excitatory amino acids
C12N 2501/845	. . Gamma amino butyric acid [GABA]
C12N 2501/85	. Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
C12N 2501/855	. . Corticotropin [ACTH]
C12N 2501/86	. . Melanocyte-stimulating hormone [MSH]
C12N 2501/90	. Polysaccharides
C12N 2501/905	. . Hyaluronic acid
C12N 2501/91	. . Heparin
C12N 2501/998	. Proteins not provided for elsewhere

NOTE

Classification by pathway does not apply.

C12N 2501/999	. Small molecules not provided for elsewhere
---------------	--

NOTE

Classification by pathway does not apply.

C12N 2502/00	Coculture with; Conditioned medium produced by
---------------------	---

C12N 2502/02	. embryonic cells
C12N 2502/025	. . extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly
C12N 2502/03	. non-embryonic pluripotent stem cells
C12N 2502/04	. germ cells
C12N 2502/07	. endocrine cells
C12N 2502/072	. . adrenal cells
C12N 2502/074	. . pinealocytes
C12N 2502/076	. . pituitary cells
C12N 2502/078	. . thyroid, parathyroid cells
C12N 2502/08	. cells of the nervous system
C12N 2502/081	. . neurons
C12N 2502/083	. . sensory transducers
C12N 2502/085	. . eye cells
C12N 2502/086	. . glial cells
C12N 2502/088	. . neural stem cells
C12N 2502/09	. epidermal cells, skin cells, oral mucosa cells
C12N 2502/091	. . melanocytes
C12N 2502/092	. . hair cells
C12N 2502/094	. . keratinocytes
C12N 2502/095	. . mammary cells
C12N 2502/097	. . oral mucosa cells
C12N 2502/098	. . cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands
C12N 2502/11	. blood or immune system cells
C12N 2502/1107	. . B cells
C12N 2502/1114	. . T cells
C12N 2502/1121	. . Dendritic cells
C12N 2502/1128	. . Erythrocytes
C12N 2502/1135	. . Granulocytes
C12N 2502/1142	. . Osteoclasts
C12N 2502/115	. . Platelets, megakaryocytes
C12N 2502/1157	. . Monocytes, macrophages
C12N 2502/1164	. . NK cells
C12N 2502/1171	. . Haematopoietic stem cells
C12N 2502/1178	. . Spleen cells
C12N 2502/1185	. . Thymus cells
C12N 2502/1192	. . Lymphatic cells
C12N 2502/13	. connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
C12N 2502/1305	. . Adipocytes

C12N 2502/1311	. . Osteocytes, osteoblasts, odontoblasts
C12N 2502/1317	. . Chondrocytes
C12N 2502/1323	. . Adult fibroblasts
C12N 2502/1329	. . Cardiomyocytes
C12N 2502/1335	. . Skeletal muscle cells, myocytes, myoblasts, myotubes
C12N 2502/1341	. . Tenocytes, cells from tendons and ligaments
C12N 2502/1347	. . Smooth muscle cells
C12N 2502/1352	. . Mesenchymal stem cells
C12N 2502/1358	. . . Bone marrow mesenchymal stem cells (BM-MSc)
C12N 2502/1364	. . . Dental pulp stem cells, dental follicle stem cells
C12N 2502/137	. . . Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood
C12N 2502/1376	. . . Mesenchymal stem cells from hair follicles
C12N 2502/1382	. . . Adipose-derived stem cells [ADSC], adipose stromal stem cells
C12N 2502/1388	. . . Mesenchymal stem cells from other natural sources
C12N 2502/1394	. . Bone marrow stromal cells; whole marrow
C12N 2502/14	. hepatocytes
C12N 2502/22	. pancreatic cells
C12N 2502/23	. Gastro-intestinal tract cells
C12N 2502/24	. Genital tract cells, non-germinal cells from gonads
C12N 2502/243	. . Cells of the female genital tract , non-germinal ovarian cells
C12N 2502/246	. . Cells of the male genital tract, non-germinal testis cells
C12N 2502/25	. Urinary tract cells, renal cells
C12N 2502/253	. . Bladder cells
C12N 2502/256	. . Renal cells
C12N 2502/27	. Lung cells, respiratory tract cells
C12N 2502/28	. Vascular endothelial cells
C12N 2502/30	. tumour cells
C12N 2502/45	. Artificially induced pluripotent stem cells
C12N 2502/50	. invertebrate cells
C12N 2502/70	. Non-animal cells
C12N 2502/99	. genetically modified cells

NOTE

Use [C12N 2501/00](#) to index the expressed products.

C12N 2503/00	Use of cells in diagnostics
C12N 2503/02	. Drug screening
C12N 2503/04	. Screening or testing on artificial tissues
C12N 2503/06	. . Screening or testing on artificial skin

C12N 2506/00**Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells****NOTE**

This scheme indexes the starting point of a differentiation process and is used in combination with classification in [C12N 5/06](#) for the end product. Differentiation of a restricted progenitor cell into its expected progeny is not indexed. Differentiation of totipotent cells and dedifferentiation are always indexed.

- C12N 2506/02 . from embryonic cells
- C12N 2506/025 . . from extra-embryonic cells, e.g. trophoblast, placenta
- C12N 2506/03 . from non-embryonic pluripotent stem cells
- C12N 2506/04 . from germ cells
- C12N 2506/07 . from endocrine cells
- C12N 2506/072 . . from adrenal cells
- C12N 2506/074 . . from pinealocytes
- C12N 2506/076 . . from pituitary cells
- C12N 2506/078 . . from thyroid, parathyroid cells
- C12N 2506/08 . from cells of the nervous system
- C12N 2506/09 . from epidermal cells, from skin cells, from oral mucosa cells
- C12N 2506/091 . . from melanocytes
- C12N 2506/092 . . from hair cells
- C12N 2506/094 . . from keratinocytes
- C12N 2506/095 . . from mammary cells
- C12N 2506/097 . . from oral mucosa cells
- C12N 2506/098 . . from cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands
- C12N 2506/11 . from blood or immune system cells
- C12N 2506/115 . . from monocytes, from macrophages
- C12N 2506/13 . from connective tissue cells, from mesenchymal cells
- C12N 2506/1307 . . from adult fibroblasts
- C12N 2506/1315 . . from cardiomyocytes
- C12N 2506/1323 . . from skeletal muscle cells
- C12N 2506/133 . . from tenocytes
- C12N 2506/1338 . . from smooth muscle cells
- C12N 2506/1346 . . from mesenchymal stem cells
- C12N 2506/1353 . . . from bone marrow mesenchymal stem cells (BM-MSC)
- C12N 2506/1361 . . . from dental pulp or dental follicle stem cells
- C12N 2506/1369 . . . from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
- C12N 2506/1376 . . . from mesenchymal stem cells derived from hair follicles
- C12N 2506/1384 . . . from adipose-derived stem cells [ADSC], from adipose stromal stem cells

- C12N 2506/1392 . . . from mesenchymal stem cells from other natural sources
- C12N 2506/14 . from hepatocytes
- C12N 2506/22 . from pancreatic cells
- C12N 2506/23 . from cells of the gastro-intestinal tract
- C12N 2506/24 . from cells of the genital tract, from non-germinal gonad cells
- C12N 2506/243 . . from cells of the female genital tract cells, from non-germinal ovarian cells
- C12N 2506/246 . . from cells of the male genital tract cells, from non-germinal testis cells
- C12N 2506/25 . from renal cells, from cells of the urinary tract
- C12N 2506/27 . from lung cells, from cells of the respiratory tract
- C12N 2506/28 . from vascular endothelial cells
- C12N 2506/30 . from cancer cells, e.g. reversion of tumour cells

NOTE

Unless the tumourigenic phenotype is totally reversed, the end product is still classified under [C12N 5/0693](#).

- C12N 2506/45 . from artificially induced pluripotent stem cells

C12N 2509/00 Methods for the dissociation of cells, e.g. specific use of enzymes

- C12N 2509/10 . Mechanical dissociation

C12N 2510/00 Genetically modified cells

- C12N 2510/02 . Cells for production
- C12N 2510/04 . Immortalised cells

C12N 2511/00 Cells for large scale production**C12N 2513/00 3D culture****C12N 2517/00 Cells related to new breeds of animals**

- C12N 2517/02 . Cells from transgenic animals
- C12N 2517/04 . Cells produced using nuclear transfer
- C12N 2517/10 . Conditioning of cells for in vitro fecondation or nuclear transfer

C12N 2521/00 Culture process characterised by the use of hydrostatic pressure, flow or shear forces

- C12N 2521/10 . Sound, e.g. ultrasounds

C12N 2523/00 Culture process characterised by temperature**C12N 2525/00 Culture process characterised by gravity, e.g. microgravity****C12N 2527/00 Culture process characterised by the use of mechanical forces, e.g. strain, vibration**

C12N 2529/00	Culture process characterised by the use of electromagnetic stimulation
C12N 2529/10	. Stimulation by light
C12N 2531/00	Microcarriers
C12N 2533/00	Supports or coatings for cell culture, characterised by material
C12N 2533/10	. Mineral substrates
C12N 2533/12	. . Glass
C12N 2533/14	. . Ceramic
C12N 2533/18	. . Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells
C12N 2533/20	. Small organic molecules
C12N 2533/30	. Synthetic polymers (thermoreactive polymers , e.g. PNIPAm, C12N 2539/10)
C12N 2533/32	. . Polylysine, polyornithine
C12N 2533/40	. . Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
C12N 2533/50	. Proteins
C12N 2533/52	. . Fibronectin; Laminin
C12N 2533/54	. . Collagen; Gelatin
C12N 2533/56	. . Fibrin; Thrombin
C12N 2533/70	. Polysaccharides
C12N 2533/72	. . Chitin, chitosan
C12N 2533/74	. . Alginate
C12N 2533/76	. . Agarose, agar-agar
C12N 2533/78	. . Cellulose
C12N 2533/80	. . Hyaluronan
C12N 2533/90	. Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
C12N 2533/92	. . Amnion; Decellularised dermis or mucosa
C12N 2535/00	Supports or coatings for cell culture characterised by topography
C12N 2535/10	. Patterned coating
C12N 2537/00	Supports and/or coatings for cell culture characterised by physical or chemical treatment
C12N 2537/10	. Cross-linking
C12N 2539/00	Supports and/or coatings for cell culture characterised by properties
C12N 2539/10	. Coating allowing for selective detachment of cells, e.g. thermoreactive coating
C12N 2700/00	Viruses
C12N 2710/00	dsDNA Viruses (not used)
C12N 2710/00011	. dsDNA Viruses
C12N 2710/00021	. . Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2710/00022	. .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2710/00023	. .	Virus like particles [VLP]
C12N 2710/00031	. .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2710/00032	. .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2710/00033	. .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2710/00034	. .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2710/00041	. .	Use of virus, viral particle or viral elements as a vector
C12N 2710/00042	. . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2710/00043	. . .	viral genome or elements thereof as genetic vector
C12N 2710/00044	. . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2710/00045	. . .	Special targeting system for viral vectors
C12N 2710/00051	. .	Methods of production or purification of viral material
C12N 2710/00052	. . .	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2710/00061	. .	Methods of inactivation or attenuation
C12N 2710/00062	. . .	by genetic engineering
C12N 2710/00063	. . .	by chemical treatment
C12N 2710/00064	. . .	by serial passage
C12N 2710/00071	. .	Demonstrated in vivo effect
C12N 2710/00088	. .	For redistribution
C12N 2710/10011	. .	Adenoviridae
C12N 2710/10021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2710/10022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2710/10023	. . .	Virus like particles [VLP]
C12N 2710/10031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2710/10032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2710/10033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2710/10034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2710/10041	. . .	Use of virus, viral particle or viral elements as a vector
C12N 2710/10042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2710/10043	viral genome or elements thereof as genetic vector
C12N 2710/10044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2710/10045	Special targeting system for viral vectors
C12N 2710/10051	. . .	Methods of production or purification of viral material

C12N 2710/10052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2710/10061	Methods of inactivation or attenuation
C12N 2710/10062	by genetic engineering
C12N 2710/10063	by chemical treatment
C12N 2710/10064	by serial passage
C12N 2710/10071	Demonstrated in vivo effect
C12N 2710/10088	For redistribution
C12N 2710/10111	Atadenovirus, e.g. ovine adenovirus D
C12N 2710/10121	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2710/10122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2710/10123	Virus like particles [VLP]
C12N 2710/10131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2710/10132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2710/10133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2710/10134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2710/10141	Use of virus, viral particle or viral elements as a vector
C12N 2710/10142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2710/10143	viral genome or elements thereof as genetic vector
C12N 2710/10144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2710/10145	Special targeting system for viral vectors
C12N 2710/10151	Methods of production or purification of viral material
C12N 2710/10152	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2710/10161	Methods of inactivation or attenuation
C12N 2710/10162	by genetic engineering
C12N 2710/10163	by chemical treatment
C12N 2710/10164	by serial passage
C12N 2710/10171	Demonstrated in vivo effect
C12N 2710/10188	For redistribution
C12N 2710/10211	Aviadenovirus, e.g. fowl adenovirus A
C12N 2710/10221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2710/10222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2710/10223	Virus like particles [VLP]
C12N 2710/10231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2710/10232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/10233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2710/10234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2710/10241	Use of virus, viral particle or viral elements as a vector
C12N 2710/10242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2710/10243	viral genome or elements thereof as genetic vector
C12N 2710/10244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2710/10245	Special targeting system for viral vectors
C12N 2710/10251	Methods of production or purification of viral material
C12N 2710/10252	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2710/10261	Methods of inactivation or attenuation
C12N 2710/10262	by genetic engineering
C12N 2710/10263	by chemical treatment
C12N 2710/10264	by serial passage
C12N 2710/10271	Demonstrated in vivo effect
C12N 2710/10288	For redistribution
C12N 2710/10311	Mastadenovirus, e.g. human or simian adenoviruses
C12N 2710/10321	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2710/10322	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2710/10323	Virus like particles [VLP]
C12N 2710/10331	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2710/10332	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2710/10333	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2710/10334	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2710/10341	Use of virus, viral particle or viral elements as a vector
C12N 2710/10342	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2710/10343	viral genome or elements thereof as genetic vector
C12N 2710/10344	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2710/10345	Special targeting system for viral vectors
C12N 2710/10351	Methods of production or purification of viral material
C12N 2710/10352	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2710/10361	Methods of inactivation or attenuation
C12N 2710/10362	by genetic engineering

C12N 2710/10363	by chemical treatment
C12N 2710/10364	by serial passage
C12N 2710/10371	Demonstrated in vivo effect
C12N 2710/10388	For redistribution
C12N 2710/12011	Asfarviridae
C12N 2710/12021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2710/12022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2710/12023	Virus like particles [VLP]
C12N 2710/12031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2710/12032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2710/12033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2710/12034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2710/12041	Use of virus, viral particle or viral elements as a vector
C12N 2710/12042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2710/12043	viral genome or elements thereof as genetic vector
C12N 2710/12044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2710/12045	Special targeting system for viral vectors
C12N 2710/12051	Methods of production or purification of viral material
C12N 2710/12052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2710/12061	Methods of inactivation or attenuation
C12N 2710/12062	by genetic engineering
C12N 2710/12063	by chemical treatment
C12N 2710/12064	by serial passage
C12N 2710/12071	Demonstrated in vivo effect
C12N 2710/12088	For redistribution
C12N 2710/14011	Baculoviridae
C12N 2710/14021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2710/14022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2710/14023	Virus like particles [VLP]
C12N 2710/14031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2710/14032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2710/14033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2710/14034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2710/14041	Use of virus, viral particle or viral elements as a vector

C12N 2710/14042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2710/14043	viral genome or elements thereof as genetic vectore
C12N 2710/14044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2710/14045	Special targeting system for viral vectors
C12N 2710/14051	Methods of production or purification of viral material
C12N 2710/14052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2710/14061	Methods of inactivation or attenuation
C12N 2710/14062	by genetic engineering
C12N 2710/14063	by chemical treatment
C12N 2710/14064	by serial passage
C12N 2710/14071	Demonstrated in vivo effect
C12N 2710/14088	For redistribution
C12N 2710/14111	Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
C12N 2710/14121	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2710/14122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2710/14123	Virus like particles [VLP]
C12N 2710/14131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2710/14132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2710/14133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2710/14134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2710/14141	Use of virus, viral particle or viral elements as a vector
C12N 2710/14142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2710/14143	viral genome or elements thereof as genetic vector
C12N 2710/14144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2710/14145	Special targeting system for viral vectors
C12N 2710/14151	Methods of production or purification of viral material
C12N 2710/14152	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2710/14161	Methods of inactivation or attenuation
C12N 2710/14162	by genetic engineering
C12N 2710/14163	by chemical treatment
C12N 2710/14164	by serial passage
C12N 2710/14171	Demonstrated in vivo effect
C12N 2710/14188	For redistribution
C12N 2710/16011	Herpesviridae

C12N 2710/16021	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2710/16022	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2710/16023	.	.	.	Virus like particles [VLP]
C12N 2710/16031	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2710/16032	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2710/16033	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2710/16034	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2710/16041	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2710/16042	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2710/16043	.	.	.	viral genome or elements thereof as genetic vector
C12N 2710/16044	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2710/16045	.	.	.	Special targeting system for viral vectors
C12N 2710/16051	.	.	.	Methods of production or purification of viral material
C12N 2710/16052	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2710/16061	.	.	.	Methods of inactivation or attenuation
C12N 2710/16062	.	.	.	by genetic engineering
C12N 2710/16063	.	.	.	by chemical treatment
C12N 2710/16064	.	.	.	by serial passage
C12N 2710/16071	.	.	.	Demonstrated in vivo effect
C12N 2710/16088	.	.	.	For redistribution
C12N 2710/16111	.	.	.	Cytomegalovirus, e.g. human herpesvirus 5
C12N 2710/16121	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2710/16122	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2710/16123	.	.	.	Virus like particles [VLP]
C12N 2710/16131	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2710/16132	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2710/16133	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2710/16134	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2710/16141	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2710/16142	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2710/16143	.	.	.	viral genome or elements thereof as genetic vector
C12N 2710/16144	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2710/16145	.	.	.	Special targeting system for viral vectors

C12N 2710/16151	Methods of production or purification of viral material
C12N 2710/16152	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2710/16161	Methods of inactivation or attenuation
C12N 2710/16162	by genetic engineering
C12N 2710/16163	by chemical treatment
C12N 2710/16164	by serial passage
C12N 2710/16171	Demonstrated in vivo effect
C12N 2710/16188	For redistribution
C12N 2710/16211	. . .	Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
C12N 2710/16221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2710/16222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2710/16223	Virus like particles [VLP]
C12N 2710/16231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2710/16232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2710/16233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2710/16234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2710/16241	Use of virus, viral particle or viral elements as a vector
C12N 2710/16242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2710/16243	viral genome or elements thereof as genetic vector
C12N 2710/16244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2710/16245	Special targeting system for viral vectors
C12N 2710/16251	Methods of production or purification of viral material
C12N 2710/16252	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2710/16261	Methods of inactivation or attenuation
C12N 2710/16262	by genetic engineering
C12N 2710/16263	by chemical treatment
C12N 2710/16264	by serial passage
C12N 2710/16271	Demonstrated in vivo effect
C12N 2710/16288	For redistribution
C12N 2710/16311	. . .	Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
C12N 2710/16321	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2710/16322	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2710/16323	Virus like particles [VLP]
C12N 2710/16331	Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/16332	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2710/16333	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2710/16334	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2710/16341	Use of virus, viral particle or viral elements as a vector
C12N 2710/16342	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2710/16343	viral genome or elements thereof as genetic vector
C12N 2710/16344	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2710/16345	Special targeting system for viral vectors
C12N 2710/16351	Methods of production or purification of viral material
C12N 2710/16352	relating to complementin g cells and packaging systems for producing virus or viral particles
C12N 2710/16361	Methods of inactivation or attenuation
C12N 2710/16362	by genetic engineering
C12N 2710/16363	by chemical treatment
C12N 2710/16364	by serial passage
C12N 2710/16371	Demonstrated in vivo effect
C12N 2710/16388	For redistribution
C12N 2710/16411	Rhadinovirus, e.g. human herpesvirus 8
C12N 2710/16421	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2710/16422	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2710/16423	Virus like particles [VLP]
C12N 2710/16431	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2710/16432	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2710/16433	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2710/16434	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2710/16441	Use of virus, viral particle or viral elements as a vector
C12N 2710/16442	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2710/16443	viral genome or elements thereof as genetic vector
C12N 2710/16444	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2710/16445	Special targeting system for viral vectors
C12N 2710/16451	Methods of production or purification of viral material
C12N 2710/16452	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2710/16461	Methods of inactivation or attenuation

C12N 2710/16462	by genetic engineering
C12N 2710/16463	by chemical treatment
C12N 2710/16464	by serial passage
C12N 2710/16471	Demonstrated in vivo effect
C12N 2710/16488	For redistribution
C12N 2710/16511	Roseolovirus, e.g. human herpesvirus 6, 7
C12N 2710/16521	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2710/16522	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2710/16523	Virus like particles [VLP]
C12N 2710/16531	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2710/16532	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2710/16533	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2710/16534	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral
C12N 2710/16541	Use of virus, viral particle or viral elements as a vector
C12N 2710/16542	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2710/16543	viral genome or elements thereof as genetic vector
C12N 2710/16544	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2710/16545	Special targeting system for viral vectors
C12N 2710/16551	Methods of production or purification of viral material
C12N 2710/16552	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2710/16561	Methods of inactivation or attenuation
C12N 2710/16562	by genetic engineering
C12N 2710/16563	by chemical treatment
C12N 2710/16564	by serial passage
C12N 2710/16571	Demonstrated in vivo effect
C12N 2710/16588	For redistribution
C12N 2710/16611	Simplexvirus, e.g. human herpesvirus 1, 2
C12N 2710/16621	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2710/16622	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2710/16623	Virus like particles [VLP]
C12N 2710/16631	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2710/16632	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2710/16633	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/16634	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2710/16641	Use of virus, viral particle or viral elements as a vector
C12N 2710/16642	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2710/16643	viral genome or elements thereof as genetic vector
C12N 2710/16644	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2710/16645	Special targeting system for viral vectors
C12N 2710/16651	Methods of production or purification of viral material
C12N 2710/16652	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2710/16661	Methods of inactivation or attenuation
C12N 2710/16662	by genetic engineering
C12N 2710/16663	by chemical treatment
C12N 2710/16664	by serial passage
C12N 2710/16671	Demonstrated in vivo effect
C12N 2710/16688	For redistribution
C12N 2710/16711	Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
C12N 2710/16721	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2710/16722	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2710/16723	Virus like particles [VLP]
C12N 2710/16731	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2710/16732	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2710/16733	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2710/16734	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2710/16741	Use of virus, viral particle or viral elements as a vector
C12N 2710/16742	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2710/16743	viral genome or elements thereof as genetic vector
C12N 2710/16744	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2710/16745	Special targeting system for viral vectors
C12N 2710/16751	Methods of production or purification of viral material
C12N 2710/16752	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2710/16761	Methods of inactivation or attenuation
C12N 2710/16762	by genetic engineering
C12N 2710/16763	by chemical treatment
C12N 2710/16764	by serial passage

C12N 2710/16771	Demonstrated in vivo effect
C12N 2710/16788	For redistribution
C12N 2710/18011	. .	Nimaviridae
C12N 2710/18021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2710/18022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2710/18023	. . .	Virus like particles [VLP]
C12N 2710/18031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2710/18032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2710/18033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2710/18034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2710/18041	. . .	Use of virus, viral particle or viral elements as a vector
C12N 2710/18042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2710/18043	viral genome or elements thereof as genetic vector
C12N 2710/18044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2710/18045	Special targeting system for viral vectors
C12N 2710/18051	. . .	Methods of production or purification of viral material
C12N 2710/18052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2710/18061	. . .	Methods of inactivation or attenuation
C12N 2710/18062	by genetic engineering
C12N 2710/18063	by chemical treatment
C12N 2710/18064	by serial passage
C12N 2710/18071	. . .	Demonstrated in vivo effect
C12N 2710/18088	. . .	For redistribution
C12N 2710/20011	. .	Papillomaviridae
C12N 2710/20021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2710/20022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2710/20023	. . .	Virus like particles [VLP]
C12N 2710/20031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2710/20032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2710/20033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2710/20034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2710/20041	. . .	Use of virus, viral particle or viral elements as a vector
C12N 2710/20042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2710/20043	viral genome or elements thereof as genetic vector

C12N 2710/20044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2710/20045	Special targeting system for viral vectors
C12N 2710/20051	Methods of production or purification of viral material
C12N 2710/20052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2710/20061	Methods of inactivation or attenuation
C12N 2710/20062	by genetic engineering
C12N 2710/20063	by chemical treatment
C12N 2710/20064	by serial passage
C12N 2710/20071	Demonstrated in vivo effect
C12N 2710/20088	For redistribution
C12N 2710/22011	Polyomaviridae, e.g. polyoma, SV40, JC
C12N 2710/22021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2710/22022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2710/22023	Virus like particles [VLP]
C12N 2710/22031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2710/22032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2710/22033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2710/22034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2710/22041	Use of virus, viral particle or viral elements as a vector
C12N 2710/22042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2710/22043	viral genome or elements thereof as genetic vector
C12N 2710/22044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2710/22045	Special targeting system for viral vectors
C12N 2710/22051	Methods of production or purification of viral material
C12N 2710/22052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2710/22061	Methods of inactivation or attenuation
C12N 2710/22062	by genetic engineering
C12N 2710/22063	by chemical treatment
C12N 2710/22064	by serial passage
C12N 2710/22071	Demonstrated in vivo effect
C12N 2710/22088	For redistribution
C12N 2710/24011	Poxviridae
C12N 2710/24021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2710/24022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/24023	.	.	.	Virus like particles [VLP]
C12N 2710/24031	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2710/24032	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2710/24033	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2710/24034	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2710/24041	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2710/24042	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2710/24043	.	.	.	viral genome or elements thereof as genetic vector
C12N 2710/24044	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2710/24045	.	.	.	Special targeting system for viral vectors
C12N 2710/24051	.	.	.	Methods of production or purification of viral material
C12N 2710/24052	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2710/24061	.	.	.	Methods of inactivation or attenuation
C12N 2710/24062	.	.	.	by genetic engineering
C12N 2710/24063	.	.	.	by chemical treatment
C12N 2710/24064	.	.	.	by serial passage
C12N 2710/24071	.	.	.	Demonstrated in vivo effect
C12N 2710/24088	.	.	.	For redistribution
C12N 2710/24111	.	.	.	Orthopoxvirus, e.g. vaccinia virus, variola
C12N 2710/24121	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2710/24122	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2710/24123	.	.	.	Virus like particles [VLP]
C12N 2710/24131	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2710/24132	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2710/24133	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2710/24134	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2710/24141	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2710/24142	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2710/24143	.	.	.	viral genome or elements thereof as genetic vector
C12N 2710/24144	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2710/24145	.	.	.	Special targeting system for viral vectors
C12N 2710/24151	.	.	.	Methods of production or purification of viral material
C12N 2710/24152	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2710/24161	Methods of inactivation or attenuation
C12N 2710/24162	by genetic engineering
C12N 2710/24163	by chemical treatment
C12N 2710/24164	by serial passage
C12N 2710/24171	Demonstrated in vivo effect
C12N 2710/24188	For redistribution
C12N 2710/24211	. . .	Parapoxvirus, e.g. Orf virus
C12N 2710/24221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2710/24222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2710/24223	Virus like particles [VLP]
C12N 2710/24231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2710/24232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2710/24233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2710/24234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2710/24241	Use of virus, viral particle or viral elements as a vector
C12N 2710/24242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2710/24243	viral genome or elements thereof as genetic vector
C12N 2710/24244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2710/24245	Special targeting system for viral vectors
C12N 2710/24251	Methods of production or purification of viral material
C12N 2710/24252	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2710/24261	Methods of inactivation or attenuation
C12N 2710/24262	by genetic engineering
C12N 2710/24263	by chemical treatment
C12N 2710/24264	by serial passage
C12N 2710/24271	Demonstrated in vivo effect
C12N 2710/24288	For redistribution
C12N 2720/00		dsRNA Viruses (not used)
C12N 2720/00011	. .	dsRNA Viruses
C12N 2720/00021	. .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2720/00022	. .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2720/00023	. .	Virus like particles [VLP]
C12N 2720/00031	. .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2720/00032	. .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- C12N 2720/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C12N 2720/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2720/00041 . . Use of virus, viral particle or viral elements as a vector
- C12N 2720/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- C12N 2720/00043 . . . viral genome or elements thereof as genetic vector
- C12N 2720/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- C12N 2720/00045 . . . Special targeting system for viral vectors
- C12N 2720/00051 . . Methods of production or purification of viral material
- C12N 2720/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2720/00061 . . Methods of inactivation or attenuation
- C12N 2720/00062 . . . by genetic engineering
- C12N 2720/00063 . . . by chemical treatment
- C12N 2720/00064 . . . by serial passage
- C12N 2720/00071 . . Demonstrated in vivo effect
- C12N 2720/00088 . . For redistribution
- C12N 2720/10011 . . Birnaviridae
- C12N 2720/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2720/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2720/10023 . . . Virus like particles [VLP]
- C12N 2720/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- C12N 2720/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2720/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C12N 2720/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2720/10041 . . . Use of virus, viral particle or viral elements as a vectorn
- C12N 2720/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- C12N 2720/10043 viral genome or elements thereof as genetic vector
- C12N 2720/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- C12N 2720/10045 Special targeting system for viral vectors
- C12N 2720/10051 . . . Methods of production or purification of viral material
- C12N 2720/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2720/10061 . . . Methods of inactivation or attenuation
- C12N 2720/10062 by genetic engineering
- C12N 2720/10063 by chemical treatment

C12N 2720/10064	by serial passage
C12N 2720/10071	. . .	Demonstrated in vivo effect
C12N 2720/10088	. . .	For redistribution
C12N 2720/12011	. .	Reoviridae
C12N 2720/12021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2720/12022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2720/12023	. . .	Virus like particles [VLP]
C12N 2720/12031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2720/12032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2720/12033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2720/12034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2720/12041	. . .	Use of virus, viral particle or viral elements as a vector
C12N 2720/12042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2720/12043	viral genome or elements thereof as genetic vector
C12N 2720/12044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2720/12045	Special targeting system for viral vectors
C12N 2720/12051	. . .	Methods of production or purification of viral material
C12N 2720/12052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2720/12061	. . .	Methods of inactivation or attenuation
C12N 2720/12062	by genetic engineering
C12N 2720/12063	by chemical treatment
C12N 2720/12064	by serial passage
C12N 2720/12071	. . .	Demonstrated in vivo effect
C12N 2720/12088	. . .	For redistribution
C12N 2720/12111	. . .	Orbivirus, e.g. bluetongue virus
C12N 2720/12121	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2720/12122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2720/12123	Virus like particles [VLP]
C12N 2720/12131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2720/12132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2720/12133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2720/12134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2720/12141	Use of virus, viral particle or viral elements as a vectorn

C12N 2720/12142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2720/12143	viral genome or elements thereof as genetic vector
C12N 2720/12144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2720/12145	Special targeting system for viral vectors
C12N 2720/12151	Methods of production or purification of viral material
C12N 2720/12152	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2720/12161	Methods of inactivation or attenuation
C12N 2720/12162	by genetic engineering
C12N 2720/12163	by chemical treatment
C12N 2720/12164	by serial passage
C12N 2720/12171	Demonstrated in vivo effect
C12N 2720/12188	For redistribution
C12N 2720/12211	Orthoreovirus, e.g. mammalian orthoreovirus
C12N 2720/12221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2720/12222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2720/12223	Virus like particles [VLP]
C12N 2720/12231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2720/12232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2720/12233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2720/12234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2720/12241	Use of virus, viral particle or viral elements as a vector
C12N 2720/12242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2720/12243	viral genome or elements thereof as genetic vector
C12N 2720/12244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2720/12245	Special targeting system for viral vectors
C12N 2720/12251	Methods of production or purification of viral material
C12N 2720/12252	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2720/12261	Methods of inactivation or attenuation
C12N 2720/12262	by genetic engineering
C12N 2720/12263	by chemical treatment
C12N 2720/12264	by serial passage
C12N 2720/12271	Demonstrated in vivo effect
C12N 2720/12288	For redistribution

C12N 2720/12311	. . .	Rotavirus, e.g. rotavirus A
C12N 2720/12321	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2720/12322	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2720/12323	Virus like particles [VLP]
C12N 2720/12331	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2720/12332	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2720/12333	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2720/12334	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2720/12341	Use of virus, viral particle or viral elements as a vector
C12N 2720/12342	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2720/12343	viral genome or elements thereof as genetic vector
C12N 2720/12344	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2720/12345	Special targeting system for viral vectors
C12N 2720/12351	Methods of production or purification of viral material
C12N 2720/12352	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2720/12361	Methods of inactivation or attenuation
C12N 2720/12362	by genetic engineering
C12N 2720/12363	by chemical treatment
C12N 2720/12364	by serial passage
C12N 2720/12371	Demonstrated in vivo effect
C12N 2720/12388	For redistribution

C12N 2730/00 **Reverse Transcribing DNA Viruses (not used)**

C12N 2730/00011	. .	Reverse Transcribing DNA Viruses
C12N 2730/00021	. .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2730/00022	. .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2730/00023	. .	Virus like particles [VLP]
C12N 2730/00031	. .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2730/00032	. .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2730/00033	. .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2730/00034	. .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2730/00041	. .	Use of virus, viral particle or viral elements as a vector
C12N 2730/00042	. . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2730/00043	. . .	viral genome or elements thereof as genetic vector

C12N 2730/00044	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2730/00045	.	.	.	Special targeting system for viral vectors
C12N 2730/00051	.	.	.	Methods of production or purification of viral material
C12N 2730/00052	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2730/00061	.	.	.	Methods of inactivation or attenuation
C12N 2730/00062	.	.	.	by genetic engineering
C12N 2730/00063	.	.	.	by chemical treatment
C12N 2730/00064	.	.	.	by serial passage
C12N 2730/00071	.	.	.	Demonstrated in vivo effect
C12N 2730/00088	.	.	.	For redistribution
C12N 2730/10011	.	.	.	Hepadnaviridae
C12N 2730/10021	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2730/10022	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2730/10023	.	.	.	Virus like particles [VLP]
C12N 2730/10031	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2730/10032	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2730/10033	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2730/10034	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2730/10041	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2730/10042	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2730/10043	.	.	.	viral genome or elements thereof as genetic vector
C12N 2730/10044	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2730/10045	.	.	.	Special targeting system for viral vectors
C12N 2730/10051	.	.	.	Methods of production or purification of viral material
C12N 2730/10052	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2730/10061	.	.	.	Methods of inactivation or attenuation
C12N 2730/10062	.	.	.	by genetic engineering
C12N 2730/10063	.	.	.	by chemical treatment
C12N 2730/10064	.	.	.	by serial passage
C12N 2730/10071	.	.	.	Demonstrated in vivo effect
C12N 2730/10088	.	.	.	For redistribution
C12N 2730/10111	.	.	.	Orthohepadnavirus, e.g. hepatitis B virus
C12N 2730/10121	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2730/10122	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2730/10123	Virus like particles [VLP]
C12N 2730/10131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2730/10132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2730/10133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2730/10134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2730/10141	Use of virus, viral particle or viral elements as a vector
C12N 2730/10142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2730/10143	viral genome or elements thereof as genetic vector
C12N 2730/10144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2730/10145	Special targeting system for viral vectors
C12N 2730/10151	Methods of production or purification of viral material
C12N 2730/10152	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2730/10161	Methods of inactivation or attenuation
C12N 2730/10162	by genetic engineering
C12N 2730/10163	by chemical treatment
C12N 2730/10164	by serial passage
C12N 2730/10171	Demonstrated in vivo effect
C12N 2730/10188	For redistribution

C12N 2740/00 **Reverse Transcribing RNA Viruses (not used)**

C12N 2740/00011	. .	Reverse Transcribing RNA Viruses
C12N 2740/00021	. .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2740/00022	. .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2740/00023	. .	Virus like particles [VLP]
C12N 2740/00031	. .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2740/00032	. .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2740/00033	. .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2740/00034	. .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2740/00041	. .	Use of virus, viral particle or viral elements as a vector
C12N 2740/00042	. . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2740/00043	. . .	viral genome or elements thereof as genetic vector
C12N 2740/00044	. . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2740/00045	. . .	Special targeting system for viral vectors
C12N 2740/00051	. .	Methods of production or purification of viral material

C12N 2740/00052	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2740/00061	.	.		Methods of inactivation or attenuation
C12N 2740/00062	.	.	.	by genetic engineering
C12N 2740/00063	.	.	.	by chemical treatment
C12N 2740/00064	.	.	.	by serial passage
C12N 2740/00071	.	.		Demonstrated in vivo effect
C12N 2740/00088	.	.		For redistribution
C12N 2740/10011	.	.		Retroviridae
C12N 2740/10021	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2740/10022	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2740/10023	.	.	.	Virus like particles [VLP]
C12N 2740/10031	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2740/10032	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2740/10033	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2740/10034	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2740/10041	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2740/10042	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2740/10043	.	.	.	viral genome or elements thereof as genetic vector
C12N 2740/10044	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2740/10045	.	.	.	Special targeting system for viral vectors
C12N 2740/10051	.	.	.	Methods of production or purification of viral material
C12N 2740/10052	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2740/10061	.	.	.	Methods of inactivation or attenuation
C12N 2740/10062	.	.	.	by genetic engineering
C12N 2740/10063	.	.	.	by chemical treatment
C12N 2740/10064	.	.	.	by serial passage
C12N 2740/10071	.	.	.	Demonstrated in vivo effect
C12N 2740/10088	.	.	.	For redistribution
C12N 2740/11011	.	.	.	Alpharetrovirus, e.g. avian leucosis virus
C12N 2740/11021	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2740/11022	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2740/11023	.	.	.	Virus like particles [VLP]
C12N 2740/11031	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2740/11032	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2740/11033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2740/11034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2740/11041	Use of virus, viral particle or viral elements as a vector
C12N 2740/11042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2740/11043	viral genome or elements thereof as genetic vector
C12N 2740/11044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2740/11045	Special targeting system for viral vectors
C12N 2740/11051	Methods of production or purification of viral material
C12N 2740/11052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2740/11061	Methods of inactivation or attenuation
C12N 2740/11062	by genetic engineering
C12N 2740/11063	by chemical treatment
C12N 2740/11064	by serial passage
C12N 2740/11071	Demonstrated in vivo effect
C12N 2740/11088	For redistribution
C12N 2740/12011	Betaretrovirus, e.g. mouse mammary tumour virus
C12N 2740/12021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2740/12022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2740/12023	Virus like particles [VLP]
C12N 2740/12031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2740/12032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2740/12033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2740/12034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2740/12041	Use of virus, viral particle or viral elements as a vector
C12N 2740/12042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2740/12043	viral genome or elements thereof as genetic vector
C12N 2740/12044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2740/12045	Special targeting system for viral vectors
C12N 2740/12051	Methods of production or purification of viral material
C12N 2740/12052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2740/12061	Methods of inactivation or attenuation
C12N 2740/12062	by genetic engineering

C12N 2740/12063	by chemical treatment
C12N 2740/12064	by serial passage
C12N 2740/12071	Demonstrated in vivo effect
C12N 2740/12088	For redistribution
C12N 2740/13011	Gammaretrovirus, e.g. murine leukaemia virus
C12N 2740/13021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2740/13022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2740/13023	Virus like particles [VLP]
C12N 2740/13031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2740/13032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2740/13033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2740/13034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2740/13041	Use of virus, viral particle or viral elements as a vector
C12N 2740/13042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2740/13043	viral genome or elements thereof as genetic vector
C12N 2740/13044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2740/13045	Special targeting system for viral vectors
C12N 2740/13051	Methods of production or purification of viral material
C12N 2740/13052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2740/13061	Methods of inactivation or attenuation
C12N 2740/13062	by genetic engineering
C12N 2740/13063	by chemical treatment
C12N 2740/13064	by serial passage
C12N 2740/13071	Demonstrated in vivo effect
C12N 2740/13088	For redistribution
C12N 2740/14011	Deltaretrovirus, e.g. bovine leukaemia virus
C12N 2740/14021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2740/14022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2740/14023	Virus like particles [VLP]
C12N 2740/14031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2740/14032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2740/14033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2740/14034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2740/14041	Use of virus, viral particle or viral elements as a vector
C12N 2740/14042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2740/14043	viral genome or elements thereof as genetic vector
C12N 2740/14044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2740/14045	Special targeting system for viral vectors
C12N 2740/14051	Methods of production or purification of viral material
C12N 2740/14052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2740/14061	Methods of inactivation or attenuation
C12N 2740/14062	by genetic engineering
C12N 2740/14063	by chemical treatment
C12N 2740/14064	by serial passage
C12N 2740/14071	Demonstrated in vivo effect
C12N 2740/14088	For redistribution
C12N 2740/15011	Lentivirus, not HIV, e.g. FIV, SIV
C12N 2740/15021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2740/15022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2740/15023	Virus like particles [VLP]
C12N 2740/15031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2740/15032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2740/15033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2740/15034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2740/15041	Use of virus, viral particle or viral elements as a vector
C12N 2740/15042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2740/15043	viral genome or elements thereof as genetic vector
C12N 2740/15044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2740/15045	Special targeting system for viral vectors
C12N 2740/15051	Methods of production or purification of viral material
C12N 2740/15052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2740/15061	Methods of inactivation or attenuation
C12N 2740/15062	by genetic engineering
C12N 2740/15063	by chemical treatment
C12N 2740/15064	by serial passage
C12N 2740/15071	Demonstrated in vivo effect

C12N 2740/15088	For redistribution
C12N 2740/16011	. . .	Human Immunodeficiency Virus, HIV
C12N 2740/16021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2740/16022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2740/16023	Virus like particles [VLP]
C12N 2740/16031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2740/16032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2740/16033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2740/16034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2740/16041	Use of virus, viral particle or viral elements as a vector
C12N 2740/16042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2740/16043 viral genome or elements thereof as genetic vector
C12N 2740/16044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2740/16045 Special targeting system for viral vectors
C12N 2740/16051	Methods of production or purification of viral material
C12N 2740/16052 relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2740/16061	Methods of inactivation or attenuation
C12N 2740/16062 by genetic engineering
C12N 2740/16063 by chemical treatment
C12N 2740/16064 by serial passage
C12N 2740/16071	Demonstrated in vivo effect
C12N 2740/16088	For redistribution
C12N 2740/16111	concerning HIV env
C12N 2740/16122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2740/16134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2740/16171 Demonstrated in vivo effect
C12N 2740/16188 For redistribution
C12N 2740/16211	concerning HIV gagpol
C12N 2740/16222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2740/16234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2740/16271 Demonstrated in vivo effect
C12N 2740/16288 For redistribution
C12N 2740/16311	concerning HIV regulatory proteins

C12N 2740/16322	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2740/16334	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2740/16371	Demonstrated in vivo effect
C12N 2740/16388	For redistribution
C12N 2740/17011	Spumavirus, e.g. chimpanzee foamy virus
C12N 2740/17021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2740/17022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2740/17023	Virus like particles [VLP]
C12N 2740/17031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2740/17032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2740/17033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2740/17034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2740/17041	Use of virus, viral particle or viral elements as a vector
C12N 2740/17042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2740/17043	viral genome or elements thereof as genetic vector
C12N 2740/17044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2740/17045	Special targeting system for viral vectors
C12N 2740/17051	Methods of production or purification of viral material
C12N 2740/17052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2740/17061	Methods of inactivation or attenuation
C12N 2740/17062	by genetic engineering
C12N 2740/17063	by chemical treatment
C12N 2740/17064	by serial passage
C12N 2740/17071	Demonstrated in vivo effect
C12N 2740/17088	For redistribution
C12N 2750/00		ssDNA Viruses (not used)
C12N 2750/00011	ssDNA Viruses
C12N 2750/00021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2750/00022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2750/00023	Virus like particles [VLP]
C12N 2750/00031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2750/00032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2750/00033	. .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2750/00034	. .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2750/00041	. .	Use of virus, viral particle or viral elements as a vector
C12N 2750/00042	. . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2750/00043	. . .	viral genome or elements thereof as genetic vector
C12N 2750/00044	. . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2750/00045	. . .	Special targeting system for viral vectors
C12N 2750/00051	. .	Methods of production or purification of viral material
C12N 2750/00052	. . .	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2750/00061	. .	Methods of inactivation or attenuation
C12N 2750/00062	. . .	by genetic engineering
C12N 2750/00063	. . .	by chemical treatment
C12N 2750/00064	. . .	by serial passage
C12N 2750/00071	. .	Demonstrated in vivo effect
C12N 2750/00088	. .	For redistribution
C12N 2750/10011	. .	Circoviridae
C12N 2750/10021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2750/10022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2750/10023	. . .	Virus like particles [VLP]
C12N 2750/10031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2750/10032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2750/10033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2750/10034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2750/10041	. . .	Use of virus, viral particle or viral elements as a vector
C12N 2750/10042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2750/10043	viral genome or elements thereof as genetic vector
C12N 2750/10044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2750/10045	Special targeting system for viral vectors
C12N 2750/10051	. . .	Methods of production or purification of viral material
C12N 2750/10052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2750/10061	. . .	Methods of inactivation or attenuation
C12N 2750/10062	by genetic engineering
C12N 2750/10063	by chemical treatment

C12N 2750/10064	by serial passage
C12N 2750/10071	. . .	Demonstrated in vivo effect
C12N 2750/10088	. . .	For redistribution
C12N 2750/12011	. .	Geminiviridae
C12N 2750/12021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2750/12022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2750/12023	. . .	Virus like particles [VLP]
C12N 2750/12031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2750/12032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2750/12033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2750/12034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2750/12041	. . .	Use of virus, viral particle or viral elements as a vector
C12N 2750/12042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2750/12043	viral genome or elements thereof as genetic vector
C12N 2750/12044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2750/12045	Special targeting system for viral vectors
C12N 2750/12051	. . .	Methods of production or purification of viral material
C12N 2750/12052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2750/12061	. . .	Methods of inactivation or attenuation
C12N 2750/12062	by genetic engineering
C12N 2750/12063	by chemical treatment
C12N 2750/12064	by serial passage
C12N 2750/12071	. . .	Demonstrated in vivo effect
C12N 2750/12088	. . .	For redistribution
C12N 2750/14011	. .	Parvoviridae
C12N 2750/14021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2750/14022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2750/14023	. . .	Virus like particles [VLP]
C12N 2750/14031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2750/14032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2750/14033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2750/14034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2750/14041	. . .	Use of virus, viral particle or viral elements as a vector
C12N 2750/14042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2750/14043	viral genome or elements thereof as genetic vector
C12N 2750/14044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2750/14045	Special targeting system for viral vectors
C12N 2750/14051	Methods of production or purification of viral material
C12N 2750/14052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2750/14061	Methods of inactivation or attenuation
C12N 2750/14062	by genetic engineering
C12N 2750/14063	by chemical treatment
C12N 2750/14064	by serial passage
C12N 2750/14071	Demonstrated in vivo effect
C12N 2750/14088	For redistribution
C12N 2750/14111	Dependovirus, e.g. adenoassociated viruses
C12N 2750/14121	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2750/14122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2750/14123	Virus like particles [VLP]
C12N 2750/14131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2750/14132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2750/14133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2750/14134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2750/14141	Use of virus, viral particle or viral elements as a vector
C12N 2750/14142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2750/14143	viral genome or elements thereof as genetic vector
C12N 2750/14144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2750/14145	Special targeting system for viral vectors
C12N 2750/14151	Methods of production or purification of viral material
C12N 2750/14152	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2750/14161	Methods of inactivation or attenuation
C12N 2750/14162	by genetic engineering
C12N 2750/14163	by chemical treatment
C12N 2750/14164	by serial passage
C12N 2750/14171	Demonstrated in vivo effect
C12N 2750/14188	For redistribution
C12N 2750/14211	Erythrovirus, e.g. B19 virus
C12N 2750/14221	Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2750/14222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2750/14223	Virus like particles [VLP]
C12N 2750/14231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2750/14232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2750/14233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2750/14234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2750/14241	Use of virus, viral particle or viral elements as a vector
C12N 2750/14242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2750/14243 viral genome or elements thereof as genetic vector
C12N 2750/14244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2750/14245 Special targeting system for viral vectors
C12N 2750/14251	Methods of production or purification of viral material
C12N 2750/14252 relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2750/14261	Methods of inactivation or attenuation
C12N 2750/14262 by genetic engineering
C12N 2750/14263 by chemical treatment
C12N 2750/14264 by serial passage
C12N 2750/14271	Demonstrated in vivo effect
C12N 2750/14288	For redistribution
C12N 2750/14311	Parvovirus, e.g. minute virus of mice
C12N 2750/14321	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2750/14322	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2750/14323	Virus like particles [VLP]
C12N 2750/14331	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2750/14332	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2750/14333	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2750/14334	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2750/14341	Use of virus, viral particle or viral elements as a vector
C12N 2750/14342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2750/14343 viral genome or elements thereof as genetic vector
C12N 2750/14344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2750/14345 Special targeting system for viral vectors

C12N 2750/14351	Methods of production or purification of viral material
C12N 2750/14352	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2750/14361	Methods of inactivation or attenuation
C12N 2750/14362	by genetic engineering
C12N 2750/14363	by chemical treatment
C12N 2750/14364	by serial passage
C12N 2750/14371	Demonstrated in vivo effect
C12N 2750/14388	For redistribution
C12N 2760/00		ssRNA Viruses negative-sense (not used)
C12N 2760/00011	. .	ssRNA Viruses negative-sense
C12N 2760/00021	. .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/00022	. .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/00023	. .	Virus like particles [VLP]
C12N 2760/00031	. .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/00032	. .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/00033	. .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/00034	. .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/00041	. .	Use of virus, viral particle or viral elements as a vector
C12N 2760/00042	. . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/00043	. . .	viral genome or elements thereof as genetic vector
C12N 2760/00044	. . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/00045	. . .	Special targeting system for viral vectors
C12N 2760/00051	. .	Methods of production or purification of viral material
C12N 2760/00052	. . .	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/00061	. .	Methods of inactivation or attenuation
C12N 2760/00062	. . .	by genetic engineering
C12N 2760/00063	. . .	by chemical treatment
C12N 2760/00064	. . .	by serial passage
C12N 2760/00071	. .	Demonstrated in vivo effect
C12N 2760/00088	. .	For redistribution
C12N 2760/10011	. .	Arenaviridae
C12N 2760/10021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/10022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/10023	. . .	Virus like particles [VLP]

C12N 2760/10031	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/10032	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/10033	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/10034	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/10041	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2760/10042	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/10043	.	.	.	viral genome or elements thereof as genetic vector
C12N 2760/10044	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/10045	.	.	.	Special targeting system for viral vectors
C12N 2760/10051	.	.	.	Methods of production or purification of viral material
C12N 2760/10052	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/10061	.	.	.	Methods of inactivation or attenuation
C12N 2760/10062	.	.	.	by genetic engineering
C12N 2760/10063	.	.	.	by chemical treatment
C12N 2760/10064	.	.	.	by serial passage
C12N 2760/10071	.	.	.	Demonstrated in vivo effect
C12N 2760/10088	.	.	.	For redistribution
C12N 2760/10111	.	.	.	Deltavirus, e.g. hepatitis delta virus
C12N 2760/10121	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/10122	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/10123	.	.	.	Virus like particles [VLP]
C12N 2760/10131	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/10132	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/10133	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/10134	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/10141	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2760/10142	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/10143	.	.	.	viral genome or elements thereof as genetic vector
C12N 2760/10144	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/10145	.	.	.	Special targeting system for viral vectors
C12N 2760/10151	.	.	.	Methods of production or purification of viral material
C12N 2760/10152	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/10161	.	.	.	Methods of inactivation or attenuation

C12N 2760/10162	by genetic engineering
C12N 2760/10163	by chemical treatment
C12N 2760/10164	by serial passage
C12N 2760/10171	Demonstrated in vivo effect
C12N 2760/10188	For redistribution
C12N 2760/12011	Bunyaviridae
C12N 2760/12021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/12022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/12023	Virus like particles [VLP]
C12N 2760/12031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/12032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/12033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/12034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/12041	Use of virus, viral particle or viral elements as a vector
C12N 2760/12042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/12043	viral genome or elements thereof as genetic vector
C12N 2760/12044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/12045	Special targeting system for viral vectors
C12N 2760/12051	Methods of production or purification of viral material
C12N 2760/12052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/12061	Methods of inactivation or attenuation
C12N 2760/12062	by genetic engineering
C12N 2760/12063	by chemical treatment
C12N 2760/12064	by serial passage
C12N 2760/12071	Demonstrated in vivo effect
C12N 2760/12088	For redistribution
C12N 2760/12111	Hantavirus, e.g. Hantaan virus
C12N 2760/12121	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/12122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/12123	Virus like particles [VLP]
C12N 2760/12131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/12132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/12133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/12134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2760/12141	Use of virus, viral particle or viral elements as a vector
C12N 2760/12142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/12143	viral genome or elements thereof as genetic vector
C12N 2760/12144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/12145	Special targeting system for viral vectors
C12N 2760/12151	Methods of production or purification of viral material
C12N 2760/12152	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/12161	Methods of inactivation or attenuation
C12N 2760/12162	by genetic engineering
C12N 2760/12163	by chemical treatment
C12N 2760/12164	by serial passage
C12N 2760/12171	Demonstrated in vivo effect
C12N 2760/12188	For redistribution
C12N 2760/12211	Phlebovirus, e.g. Rift Valley fever virus
C12N 2760/12221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/12222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/12223	Virus like particles [VLP]
C12N 2760/12231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/12232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/12233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/12234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/12241	Use of virus, viral particle or viral elements as a vector
C12N 2760/12242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/12243	viral genome or elements thereof as genetic vector
C12N 2760/12244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/12245	Special targeting system for viral vectors
C12N 2760/12251	Methods of production or purification of viral material
C12N 2760/12252	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/12261	Methods of inactivation or attenuation
C12N 2760/12262	by genetic engineering
C12N 2760/12263	by chemical treatment
C12N 2760/12264	by serial passage
C12N 2760/12271	Demonstrated in vivo effect

C12N 2760/12288	For redistribution
C12N 2760/14011	. .	Filoviridae
C12N 2760/14021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/14022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/14023	. . .	Virus like particles [VLP]
C12N 2760/14031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/14032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/14033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/14034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/14041	. . .	Use of virus, viral particle or viral elements as a vector
C12N 2760/14042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/14043	viral genome or elements thereof as genetic vector
C12N 2760/14044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/14045	Special targeting system for viral vectors
C12N 2760/14051	. . .	Methods of production or purification of viral material
C12N 2760/14052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/14061	. . .	Methods of inactivation or attenuation
C12N 2760/14062	by genetic engineering
C12N 2760/14063	by chemical treatment
C12N 2760/14064	by serial passage
C12N 2760/14071	. . .	Demonstrated in vivo effect
C12N 2760/14088	. . .	For redistribution
C12N 2760/14111	. . .	Ebolavirus, e.g. Zaire ebolavirus
C12N 2760/14121	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/14122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/14123	Virus like particles [VLP]
C12N 2760/14131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/14132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/14133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/14134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/14141	Use of virus, viral particle or viral elements as a vector
C12N 2760/14142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/14143	viral genome or elements thereof as genetic vector

C12N 2760/14144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/14145	Special targeting system for viral vectors
C12N 2760/14151	Methods of production or purification of viral material
C12N 2760/14152	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/14161	Methods of inactivation or attenuation
C12N 2760/14162	by genetic engineering
C12N 2760/14163	by chemical treatment
C12N 2760/14164	by serial passage
C12N 2760/14171	Demonstrated in vivo effect
C12N 2760/14188	For redistribution
C12N 2760/14211	Marburgvirus, e.g. lake Victoria marburgvirus
C12N 2760/14221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/14222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/14223	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/14231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/14232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/14233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/14234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/14241	Use of virus, viral particle or viral elements as a vector
C12N 2760/14242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/14243	viral genome or elements thereof as genetic vector
C12N 2760/14244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/14245	Special targeting system for viral vectors
C12N 2760/14251	Methods of production or purification of viral material
C12N 2760/14252	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/14261	Methods of inactivation or attenuation
C12N 2760/14262	by genetic engineering
C12N 2760/14263	by chemical treatment
C12N 2760/14264	by serial passage
C12N 2760/14271	Demonstrated in vivo effect
C12N 2760/14288	For redistribution
C12N 2760/16011	Orthomyxoviridae
C12N 2760/16021	Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2760/16022	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/16023	.	.	.	Virus like particles [VLP]
C12N 2760/16031	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/16032	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/16033	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/16034	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/16041	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2760/16042	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/16043	.	.	.	viral genome or elements thereof as genetic vector
C12N 2760/16044	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/16045	.	.	.	Special targeting system for viral vectors
C12N 2760/16051	.	.	.	Methods of production or purification of viral material
C12N 2760/16052	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/16061	.	.	.	Methods of inactivation or attenuation
C12N 2760/16062	.	.	.	by genetic engineering
C12N 2760/16063	.	.	.	by chemical treatment
C12N 2760/16064	.	.	.	by serial passage
C12N 2760/16071	.	.	.	Demonstrated in vivo effect
C12N 2760/16088	.	.	.	For redistribution
C12N 2760/16111	.	.	.	Influenzavirus A, i.e. influenza A virus
C12N 2760/16121	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/16122	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/16123	.	.	.	Virus like particles [VLP]
C12N 2760/16131	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/16132	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/16133	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/16134	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/16141	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2760/16142	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/16143	.	.	.	viral genome or elements thereof as genetic vector
C12N 2760/16144	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/16145	.	.	.	Special targeting system for viral vectors
C12N 2760/16151	.	.	.	Methods of production or purification of viral material

C12N 2760/16152	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/16161	Methods of inactivation or attenuation
C12N 2760/16162	by genetic engineering
C12N 2760/16163	by chemical treatment
C12N 2760/16164	by serial passage
C12N 2760/16171	Demonstrated in vivo effect
C12N 2760/16188	For redistribution
C12N 2760/16211	Influenzavirus B, i.e. influenza B virus
C12N 2760/16221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/16222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/16223	Virus like particles [VLP]
C12N 2760/16231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/16232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/16233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/16234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/16241	Use of virus, viral particle or viral elements as a vector
C12N 2760/16242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/16243	viral genome or elements thereof as genetic vector
C12N 2760/16244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/16245	Special targeting system for viral vectors
C12N 2760/16251	Methods of production or purification of viral material
C12N 2760/16252	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/16261	Methods of inactivation or attenuation
C12N 2760/16262	by genetic engineering
C12N 2760/16263	by chemical treatment
C12N 2760/16264	by serial passage
C12N 2760/16271	Demonstrated in vivo effect
C12N 2760/16288	For redistribution
C12N 2760/16311	Influenzavirus C, i.e. influenza C virus
C12N 2760/16321	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/16322	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/16323	Virus like particles [VLP]
C12N 2760/16331	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/16332	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2760/16333	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/16334	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/16341	Use of virus, viral particle or viral elements as a vector
C12N 2760/16342	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/16343	viral genome or elements thereof as genetic vector
C12N 2760/16344	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/16345	Special targeting system for viral vectors
C12N 2760/16351	Methods of production or purification of viral material
C12N 2760/16352	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/16361	Methods of inactivation or attenuation
C12N 2760/16362	by genetic engineering
C12N 2760/16363	by chemical treatment
C12N 2760/16364	by serial passage
C12N 2760/16371	Demonstrated in vivo effect
C12N 2760/16388	For redistribution
C12N 2760/18011	.	.			Paramyxoviridae
C12N 2760/18021	.	.	.		Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/18022	.	.	.		New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/18023	.	.	.		Virus like particles [VLP]
C12N 2760/18031	.	.	.		Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/18032	.	.	.		Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/18033	.	.	.		Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/18034	.	.	.		Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/18041	.	.	.		Use of virus, viral particle or viral elements as a vector
C12N 2760/18042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/18043	viral genome or elements thereof as genetic vector
C12N 2760/18044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/18045	Special targeting system for viral vectors
C12N 2760/18051	.	.	.		Methods of production or purification of viral material
C12N 2760/18052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/18061	.	.	.		Methods of inactivation or attenuation
C12N 2760/18062	by genetic engineering
C12N 2760/18063	by chemical treatment

C12N 2760/18064	by serial passage
C12N 2760/18071	Demonstrated in vivo effect
C12N 2760/18088	For redistribution
C12N 2760/18111	Avulavirus, e.g. Newcastle disease virus
C12N 2760/18121	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/18122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/18123	Virus like particles [VLP]
C12N 2760/18131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/18132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/18133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/18134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/18141	Use of virus, viral particle or viral elements as a vector
C12N 2760/18142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/18143	viral genome or elements thereof as genetic vector
C12N 2760/18144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/18145	Special targeting system for viral vectors
C12N 2760/18151	Methods of production or purification of viral material
C12N 2760/18152	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/18161	Methods of inactivation or attenuation
C12N 2760/18162	by genetic engineering
C12N 2760/18163	by chemical treatment
C12N 2760/18164	by serial passage
C12N 2760/18171	Demonstrated in vivo effect
C12N 2760/18188	For redistribution
C12N 2760/18211	Henipavirus, e.g. hendra virus
C12N 2760/18221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/18222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/18223	Virus like particles [VLP]
C12N 2760/18231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/18232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/18233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/18234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/18241	Use of virus, viral particle or viral elements as a vector

C12N 2760/18242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/18243	viral genome or elements thereof as genetic vector
C12N 2760/18244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/18245	Special targeting system for viral vectors
C12N 2760/18251	Methods of production or purification of viral material
C12N 2760/18252	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/18261	Methods of inactivation or attenuation
C12N 2760/18262	by genetic engineering
C12N 2760/18263	by chemical treatment
C12N 2760/18264	by serial passage
C12N 2760/18271	Demonstrated in vivo effect
C12N 2760/18288	For redistribution
C12N 2760/18311	Metapneumovirus, e.g. avian pneumovirus
C12N 2760/18321	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/18322	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/18323	Virus like particles [VLP]
C12N 2760/18331	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/18332	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/18333	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/18334	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/18341	Use of virus, viral particle or viral elements as a vector
C12N 2760/18342	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/18343	viral genome or elements thereof as genetic vector
C12N 2760/18344	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/18345	Special targeting system for viral vectors
C12N 2760/18351	Methods of production or purification of viral material
C12N 2760/18352	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/18361	Methods of inactivation or attenuation
C12N 2760/18362	by genetic engineering
C12N 2760/18363	by chemical treatment
C12N 2760/18364	by serial passage
C12N 2760/18371	Demonstrated in vivo effect
C12N 2760/18388	For redistribution

C12N 2760/18411	.	.	.	Morbillivirus, e.g. Measles virus, canine distemper
C12N 2760/18421	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/18422	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/18423	.	.	.	Virus like particles [VLP]
C12N 2760/18431	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/18432	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/18433	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/18434	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/18441	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2760/18442	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/18443	.	.	.	viral genome or elements thereof as genetic vector
C12N 2760/18444	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/18445	.	.	.	Special targeting system for viral vectors
C12N 2760/18451	.	.	.	Methods of production or purification of viral material
C12N 2760/18452	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/18461	.	.	.	Methods of inactivation or attenuation
C12N 2760/18462	.	.	.	by genetic engineering
C12N 2760/18463	.	.	.	by chemical treatment
C12N 2760/18464	.	.	.	by serial passage
C12N 2760/18471	.	.	.	Demonstrated in vivo effect
C12N 2760/18488	.	.	.	For redistribution
C12N 2760/18511	.	.	.	Pneumovirus, e.g. human respiratory syncytial virus
C12N 2760/18521	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/18522	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/18523	.	.	.	Virus like particles [VLP]
C12N 2760/18531	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/18532	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/18533	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/18534	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/18541	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2760/18542	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/18543	.	.	.	viral genome or elements thereof as genetic vector

C12N 2760/18544	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/18545	Special targeting system for viral vectors
C12N 2760/18551	Methods of production or purification of viral material
C12N 2760/18552	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/18561	Methods of inactivation or attenuation
C12N 2760/18562	by genetic engineering
C12N 2760/18563	by chemical treatment
C12N 2760/18564	by serial passage
C12N 2760/18571	Demonstrated in vivo effect
C12N 2760/18588	For redistribution
C12N 2760/18611	Respirovirus, e.g. Bovine, human parainfluenza 1,3
C12N 2760/18621	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/18622	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/18623	Virus like particles [VLP]
C12N 2760/18631	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/18632	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/18633	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/18634	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/18641	Use of virus, viral particle or viral elements as a vector
C12N 2760/18642	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/18643	viral genome or elements thereof as genetic vector
C12N 2760/18644	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/18645	Special targeting system for viral vectors
C12N 2760/18651	Methods of production or purification of viral material
C12N 2760/18652	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/18661	Methods of inactivation or attenuation
C12N 2760/18662	by genetic engineering
C12N 2760/18663	by chemical treatment
C12N 2760/18664	by serial passage
C12N 2760/18671	Demonstrated in vivo effect
C12N 2760/18688	For redistribution
C12N 2760/18711	Rubulavirus, e.g. mumps virus, parainfluenza 2,4
C12N 2760/18721	Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2760/18722	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/18723	Virus like particles [VLP]
C12N 2760/18731	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/18732	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/18733	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/18734	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/18741	Use of virus, viral particle or viral elements as a vector
C12N 2760/18742 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/18743 viral genome or elements thereof as genetic vector
C12N 2760/18744 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/18745 Special targeting system for viral vectors
C12N 2760/18751	Methods of production or purification of viral material
C12N 2760/18752 relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/18761	Methods of inactivation or attenuation
C12N 2760/18762 by genetic engineering
C12N 2760/18763 by chemical treatment
C12N 2760/18764 by serial passage
C12N 2760/18771	Demonstrated in vivo effect
C12N 2760/18788	For redistribution
C12N 2760/18811	Sendai virus
C12N 2760/18821	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/18822	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/18823	Virus like particles [VLP]
C12N 2760/18831	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/18832	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/18833	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/18834	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/18841	Use of virus, viral particle or viral elements as a vector
C12N 2760/18842 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/18843 viral genome or elements thereof as genetic vector
C12N 2760/18845 Special targeting system for viral vectors
C12N 2760/18851	Methods of production or purification of viral material

C12N 2760/18852	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/18861	Methods of inactivation or attenuation
C12N 2760/18862	by genetic engineering
C12N 2760/18863	by chemical treatment
C12N 2760/18864	by serial passage
C12N 2760/18871	Demonstrated in vivo effect
C12N 2760/18888	For redistribution
C12N 2760/20011	Rhabdoviridae
C12N 2760/20021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/20022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/20023	Virus like particles [VLP]
C12N 2760/20031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/20032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/20033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/20034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/20041	Use of virus, viral particle or viral elements as a vector
C12N 2760/20042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/20043	viral genome or elements thereof as genetic vector
C12N 2760/20044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/20045	Special targeting system for viral vectors
C12N 2760/20051	Methods of production or purification of viral material
C12N 2760/20052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/20061	Methods of inactivation or attenuation
C12N 2760/20062	by genetic engineering
C12N 2760/20063	by chemical treatment
C12N 2760/20064	by serial passage
C12N 2760/20071	Demonstrated in vivo effect
C12N 2760/20088	For redistribution
C12N 2760/20111	Lyssavirus, e.g. rabies virus
C12N 2760/20121	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/20122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/20123	Virus like particles [VLP]
C12N 2760/20131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/20132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2760/20133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/20134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/20141	Use of virus, viral particle or viral elements as a vector
C12N 2760/20142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/20143	viral genome or elements thereof as genetic vector
C12N 2760/20144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/20145	Special targeting system for viral vectors
C12N 2760/20151	Methods of production or purification of viral material
C12N 2760/20152	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/20161	Methods of inactivation or attenuation
C12N 2760/20162	by genetic engineering
C12N 2760/20163	by chemical treatment
C12N 2760/20164	by serial passage
C12N 2760/20171	Demonstrated in vivo effect
C12N 2760/20188	For redistribution
C12N 2760/20211	Vesiculovirus, e.g. vesicular stomatitis Indiana virus
C12N 2760/20221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/20222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2760/20223	Virus like particles [VLP]
C12N 2760/20231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2760/20232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/20233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2760/20234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2760/20241	Use of virus, viral particle or viral elements as a vector
C12N 2760/20242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2760/20243	viral genome or elements thereof as genetic vector
C12N 2760/20244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2760/20245	Special targeting system for viral vectors
C12N 2760/20251	Methods of production or purification of viral material
C12N 2760/20252	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2760/20261	Methods of inactivation or attenuation
C12N 2760/20262	by genetic engineering

C12N 2760/20263	by chemical treatment
C12N 2760/20264	by serial passage
C12N 2760/20271	Demonstrated in vivo effect
C12N 2760/20288	For redistribution
C12N 2770/00		ssRNA Viruses positive-sense (not used)
C12N 2770/00011	ssRNA Viruses positive-sense
C12N 2770/00021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/00022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/00023	Virus like particles [VLP]
C12N 2770/00031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/00032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/00033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/00034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/00041	Use of virus, viral particle or viral elements as a vector
C12N 2770/00042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/00043	viral genome or elements thereof as genetic vector
C12N 2770/00044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/00045	Special targeting system for viral vectors
C12N 2770/00051	Methods of production or purification of viral material
C12N 2770/00052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/00061	Methods of inactivation or attenuation
C12N 2770/00062	by genetic engineering
C12N 2770/00063	by chemical treatment
C12N 2770/00064	by serial passage
C12N 2770/00071	Demonstrated in vivo effect
C12N 2770/00088	For redistribution
C12N 2770/10011	Arteriviridae
C12N 2770/10021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/10022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/10023	Virus like particles [VLP]
C12N 2770/10031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/10032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/10033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/10034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2770/10041	. . .	Use of virus, viral particle or viral elements as a vector
C12N 2770/10042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/10043	viral genome or elements thereof as genetic vector
C12N 2770/10044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/10045	Special targeting system for viral vectors
C12N 2770/10051	. . .	Methods of production or purification of viral material
C12N 2770/10052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/10061	. . .	Methods of inactivation or attenuation
C12N 2770/10062	by genetic engineering
C12N 2770/10063	by chemical treatment
C12N 2770/10064	by serial passage
C12N 2770/10071	. . .	Demonstrated in vivo effect
C12N 2770/10088	. . .	For redistribution
C12N 2770/12011	. .	Astroviridae
C12N 2770/12021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/12022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/12023	. . .	Virus like particles [VLP]
C12N 2770/12031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/12032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/12033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/12034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/12041	. . .	Use of virus, viral particle or viral elements as a vector
C12N 2770/12042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/12043	viral genome or elements thereof as genetic vector
C12N 2770/12044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/12045	Special targeting system for viral vectors
C12N 2770/12051	. . .	Methods of production or purification of viral material
C12N 2770/12052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/12061	. . .	Methods of inactivation or attenuation
C12N 2770/12062	by genetic engineering
C12N 2770/12063	by chemical treatment
C12N 2770/12064	by serial passage
C12N 2770/12071	. . .	Demonstrated in vivo effect
C12N 2770/12088	. . .	For redistribution
C12N 2770/14011	. .	Bromoviridae

C12N 2770/14021	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/14022	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/14023	.	.	.	Virus like particles [VLP]
C12N 2770/14031	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/14032	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/14033	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/14034	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/14041	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2770/14042	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/14043	.	.	.	viral genome or elements thereof as genetic vector
C12N 2770/14044	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/14045	.	.	.	Special targeting system for viral vectors
C12N 2770/14051	.	.	.	Methods of production or purification of viral material
C12N 2770/14052	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/14061	.	.	.	Methods of inactivation or attenuation
C12N 2770/14062	.	.	.	by genetic engineering
C12N 2770/14063	.	.	.	by chemical treatment
C12N 2770/14064	.	.	.	by serial passage
C12N 2770/14071	.	.	.	Demonstrated in vivo effect
C12N 2770/14088	.	.	.	For redistribution
C12N 2770/16011	.	.		Caliciviridae
C12N 2770/16021	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/16022	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/16023	.	.	.	Virus like particles [VLP]
C12N 2770/16031	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/16032	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/16033	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/16034	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/16041	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2770/16042	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/16043	.	.	.	viral genome or elements thereof as genetic vector
C12N 2770/16044	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/16045	.	.	.	Special targeting system for viral vectors

C12N 2770/16051	. . .	Methods of production or purification of viral material
C12N 2770/16052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/16061	. . .	Methods of inactivation or attenuation
C12N 2770/16062	by genetic engineering
C12N 2770/16063	by chemical treatment
C12N 2770/16064	by serial passage
C12N 2770/16071	. . .	Demonstrated in vivo effect
C12N 2770/16088	. . .	For redistribution
C12N 2770/18011	. .	Comoviridae
C12N 2770/18021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/18022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/18023	. . .	Virus like particles [VLP]
C12N 2770/18031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/18032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/18033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/18034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/18041	. . .	Use of virus, viral particle or viral elements as a vector
C12N 2770/18042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/18043	viral genome or elements thereof as genetic vector
C12N 2770/18044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/18045	Special targeting system for viral vectors
C12N 2770/18051	. . .	Methods of production or purification of viral material
C12N 2770/18052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/18061	. . .	Methods of inactivation or attenuation
C12N 2770/18062	by genetic engineering
C12N 2770/18063	by chemical treatment
C12N 2770/18064	by serial passage
C12N 2770/18071	. . .	Demonstrated in vivo effect
C12N 2770/18088	. . .	For redistribution
C12N 2770/20011	. .	Coronaviridae
C12N 2770/20021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/20022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/20023	. . .	Virus like particles [VLP]
C12N 2770/20031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/20032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2770/20033	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/20034	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/20041	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2770/20042	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/20043	.	.	.	viral genome or elements thereof as genetic vector
C12N 2770/20044	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/20045	.	.	.	Special targeting system for viral vectors
C12N 2770/20051	.	.	.	Methods of production or purification of viral material
C12N 2770/20052	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/20061	.	.	.	Methods of inactivation or attenuation
C12N 2770/20062	.	.	.	by genetic engineering
C12N 2770/20063	.	.	.	by chemical treatment
C12N 2770/20064	.	.	.	by serial passage
C12N 2770/20071	.	.	.	Demonstrated in vivo effect
C12N 2770/20088	.	.	.	For redistribution
C12N 2770/22011	.	.	.	Dicistroviridae
C12N 2770/22021	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/22022	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/22023	.	.	.	Virus like particles [VLP]
C12N 2770/22031	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/22032	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/22033	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/22034	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/22041	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2770/22042	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/22043	.	.	.	viral genome or elements thereof as genetic vector
C12N 2770/22044	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/22045	.	.	.	Special targeting system for viral vectors
C12N 2770/22051	.	.	.	Methods of production or purification of viral material
C12N 2770/22052	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/22061	.	.	.	Methods of inactivation or attenuation
C12N 2770/22062	.	.	.	by genetic engineering
C12N 2770/22063	.	.	.	by chemical treatment

C12N 2770/22064	by serial passage
C12N 2770/22071	. . .	Demonstrated in vivo effect
C12N 2770/22088	. . .	For redistribution
C12N 2770/24011	. .	Flaviviridae
C12N 2770/24021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/24022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/24023	. . .	Virus like particles [VLP]
C12N 2770/24031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/24032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/24033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/24034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/24041	. . .	Use of virus, viral particle or viral elements as a vector
C12N 2770/24042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/24043	viral genome or elements thereof as genetic vector
C12N 2770/24044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/24045	Special targeting system for viral vectors
C12N 2770/24051	. . .	Methods of production or purification of viral material
C12N 2770/24052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/24061	. . .	Methods of inactivation or attenuation
C12N 2770/24062	by genetic engineering
C12N 2770/24063	by chemical treatment
C12N 2770/24064	by serial passage
C12N 2770/24071	. . .	Demonstrated in vivo effect
C12N 2770/24088	. . .	For redistribution
C12N 2770/24111	. . .	Flavivirus, e.g. yellow fever virus, dengue, JEV
C12N 2770/24121	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/24122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/24123	Virus like particles [VLP]
C12N 2770/24131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/24132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/24133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/24134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/24141	Use of virus, viral particle or viral elements as a vector

C12N 2770/24142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/24143	viral genome or elements thereof as genetic vector
C12N 2770/24144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/24145	Special targeting system for viral vectors
C12N 2770/24151	Methods of production or purification of viral material
C12N 2770/24152	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/24161	Methods of inactivation or attenuation
C12N 2770/24162	by genetic engineering
C12N 2770/24163	by chemical treatment
C12N 2770/24164	by serial passage
C12N 2770/24171	Demonstrated in vivo effect
C12N 2770/24188	For redistribution
C12N 2770/24211	Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
C12N 2770/24221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/24222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/24223	Virus like particles [VLP]
C12N 2770/24231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/24232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/24233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/24234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/24241	Use of virus, viral particle or viral elements as a vector
C12N 2770/24242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/24243	viral genome or elements thereof as genetic vector
C12N 2770/24244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/24245	Special targeting system for viral vectors
C12N 2770/24251	Methods of production or purification of viral material
C12N 2770/24252	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/24261	Methods of inactivation or attenuation
C12N 2770/24262	by genetic engineering
C12N 2770/24263	by chemical treatment
C12N 2770/24264	by serial passage
C12N 2770/24271	Demonstrated in vivo effect
C12N 2770/24288	For redistribution

C12N 2770/24311	.	.	.	Pestivirus, e.g. bovine viral diarrhea virus
C12N 2770/24321	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/24322	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/24323	.	.	.	Virus like particles [VLP]
C12N 2770/24331	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/24332	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/24333	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/24334	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/24341	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2770/24342	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/24343	.	.	.	viral genome or elements thereof as genetic vector
C12N 2770/24344	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/24345	.	.	.	Special targeting system for viral vectors
C12N 2770/24351	.	.	.	Methods of production or purification of viral material
C12N 2770/24352	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/24361	.	.	.	Methods of inactivation or attenuation
C12N 2770/24362	.	.	.	by genetic engineering
C12N 2770/24363	.	.	.	by chemical treatment
C12N 2770/24364	.	.	.	by serial passage
C12N 2770/24371	.	.	.	Demonstrated in vivo effect
C12N 2770/24388	.	.	.	For redistribution
C12N 2770/26011	.	.		Flexiviridae
C12N 2770/26021	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/26022	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/26023	.	.	.	Virus like particles [VLP]
C12N 2770/26031	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/26032	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/26033	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/26034	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/26041	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2770/26042	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/26043	.	.	.	viral genome or elements thereof as genetic vector
C12N 2770/26044	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2770/26045	Special targeting system for viral vectors
C12N 2770/26051	. . .	Methods of production or purification of viral material
C12N 2770/26052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/26061	. . .	Methods of inactivation or attenuation
C12N 2770/26062	by genetic engineering
C12N 2770/26063	by chemical treatment
C12N 2770/26064	by serial passage
C12N 2770/26071	. . .	Demonstrated in vivo effect
C12N 2770/26088	. . .	For redistribution
C12N 2770/28011	. .	Hepeviridae
C12N 2770/28021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/28022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/28023	. . .	Virus like particles [VLP]
C12N 2770/28031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/28032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/28033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/28034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/28041	. . .	Use of virus, viral particle or viral elements as a vector
C12N 2770/28042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/28043	viral genome or elements thereof as genetic vector
C12N 2770/28044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/28045	Special targeting system for viral vectors
C12N 2770/28051	. . .	Methods of production or purification of viral material
C12N 2770/28052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/28061	. . .	Methods of inactivation or attenuation
C12N 2770/28062	by genetic engineering
C12N 2770/28063	by chemical treatment
C12N 2770/28064	by serial passage
C12N 2770/28071	. . .	Demonstrated in vivo effect
C12N 2770/28088	. . .	For redistribution
C12N 2770/28111	. . .	Hepevirus, e.g. hepatitis E virus
C12N 2770/28121	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/28122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/28123	Virus like particles [VLP]
C12N 2770/28131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2770/28132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/28133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/28134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/28141	Use of virus, viral particle or viral elements as a vector
C12N 2770/28142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/28143	viral genome or elements thereof as genetic vector
C12N 2770/28144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/28145	Special targeting system for viral vectors
C12N 2770/28151	Methods of production or purification of viral material
C12N 2770/28152	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/28161	Methods of inactivation or attenuation
C12N 2770/28162	by genetic engineering
C12N 2770/28163	by chemical treatment
C12N 2770/28164	by serial passage
C12N 2770/28171	Demonstrated in vivo effect
C12N 2770/28188	For redistribution
C12N 2770/30011	.	.			Nodaviridae
C12N 2770/30021	.	.	.		Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/30022	.	.	.		New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/30023	.	.	.		Virus like particles [VLP]
C12N 2770/30031	.	.	.		Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/30032	.	.	.		Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/30033	.	.	.		Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/30034	.	.	.		Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/30041	.	.	.		Use of virus, viral particle or viral elements as a vector
C12N 2770/30042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/30043	viral genome or elements thereof as genetic vector
C12N 2770/30044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/30045	Special targeting system for viral vectors
C12N 2770/30051	Methods of production or purification of viral material
C12N 2770/30052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/30061	Methods of inactivation or attenuation
C12N 2770/30062	by genetic engineering

C12N 2770/30063	by chemical treatment
C12N 2770/30064	by serial passage
C12N 2770/30071	. . .	Demonstrated in vivo effect
C12N 2770/30088	. . .	For redistribution
C12N 2770/32011	. .	Picornaviridae
C12N 2770/32021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/32022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/32023	. . .	Virus like particles [VLP]
C12N 2770/32031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/32032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/32033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/32034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/32041	. . .	Use of virus, viral particle or viral elements as a vector
C12N 2770/32042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/32043	viral genome or elements thereof as genetic vector
C12N 2770/32044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/32045	Special targeting system for viral vectors
C12N 2770/32051	. . .	Methods of production or purification of viral material
C12N 2770/32052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/32061	. . .	Methods of inactivation or attenuation
C12N 2770/32062	by genetic engineering
C12N 2770/32063	by chemical treatment
C12N 2770/32064	by serial passage
C12N 2770/32071	. . .	Demonstrated in vivo effect
C12N 2770/32088	. . .	For redistribution
C12N 2770/32111	. . .	Aphthovirus, e.g. footandmouth disease virus
C12N 2770/32121	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/32122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/32123	Virus like particles [VLP]
C12N 2770/32131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/32132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/32133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/32134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/32141	Use of virus, viral particle or viral elements as a vector

C12N 2770/32142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/32143	viral genome or elements thereof as genetic vector
C12N 2770/32144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/32145	Special targeting system for viral vectors
C12N 2770/32151	Methods of production or purification of viral material
C12N 2770/32152	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/32161	Methods of inactivation or attenuation
C12N 2770/32162	by genetic engineering
C12N 2770/32163	by chemical treatment
C12N 2770/32164	by serial passage
C12N 2770/32171	Demonstrated in vivo effect
C12N 2770/32188	For redistribution
C12N 2770/32211	Cardiovirus, e.g. encephalomyocarditis virus
C12N 2770/32221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/32222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/32223	Virus like particles [VLP]
C12N 2770/32231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/32232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/32233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/32234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/32241	Use of virus, viral particle or viral elements as a vector
C12N 2770/32242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/32243	viral genome or elements thereof as genetic vector
C12N 2770/32244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/32245	Special targeting system for viral vectors
C12N 2770/32251	Methods of production or purification of viral material
C12N 2770/32252	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/32261	Methods of inactivation or attenuation
C12N 2770/32262	by genetic engineering
C12N 2770/32263	by chemical treatment
C12N 2770/32264	by serial passage
C12N 2770/32271	Demonstrated in vivo effect
C12N 2770/32288	For redistribution

C12N 2770/32311	.	.	.	Enterovirus
C12N 2770/32321	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/32322	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/32323	.	.	.	Virus like particles [VLP]
C12N 2770/32331	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/32332	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/32333	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/32334	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/32341	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2770/32342	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/32343	.	.	.	viral genome or elements thereof as genetic vector
C12N 2770/32344	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/32345	.	.	.	Special targeting system for viral vectors
C12N 2770/32351	.	.	.	Methods of production or purification of viral material
C12N 2770/32352	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/32361	.	.	.	Methods of inactivation or attenuation
C12N 2770/32362	.	.	.	by genetic engineering
C12N 2770/32363	.	.	.	by chemical treatment
C12N 2770/32364	.	.	.	by serial passage
C12N 2770/32371	.	.	.	Demonstrated in vivo effect
C12N 2770/32388	.	.	.	For redistribution
C12N 2770/32411	.	.	.	Hepatovirus, i.e. hepatitis A virus
C12N 2770/32421	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/32422	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/32423	.	.	.	Virus like particles [VLP]
C12N 2770/32431	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/32432	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/32433	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/32434	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/32441	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2770/32442	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/32443	.	.	.	viral genome or elements thereof as genetic vector

C12N 2770/32444	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/32445	Special targeting system for viral vectors
C12N 2770/32451	Methods of production or purification of viral material
C12N 2770/32452	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/32461	Methods of inactivation or attenuation
C12N 2770/32462	by genetic engineering
C12N 2770/32463	by chemical treatment
C12N 2770/32464	by serial passage
C12N 2770/32471	Demonstrated in vivo effect
C12N 2770/32488	For redistribution
C12N 2770/32511	Parechovirus, e.g. human parechovirus
C12N 2770/32521	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/32522	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/32523	Virus like particles [VLP]
C12N 2770/32531	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/32532	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/32533	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/32534	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/32541	Use of virus, viral particle or viral elements as a vector
C12N 2770/32542	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/32543	viral genome or elements thereof as genetic vector
C12N 2770/32544	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/32545	Special targeting system for viral vectors
C12N 2770/32551	Methods of production or purification of viral material
C12N 2770/32552	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/32561	Methods of inactivation or attenuation
C12N 2770/32562	by genetic engineering
C12N 2770/32563	by chemical treatment
C12N 2770/32564	by serial passage
C12N 2770/32571	Demonstrated in vivo effect
C12N 2770/32588	For redistribution
C12N 2770/32611	Poliovirus
C12N 2770/32621	Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2770/32622	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/32623	Virus like particles [VLP]
C12N 2770/32631	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/32632	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/32633	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/32634	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/32641	Use of virus, viral particle or viral elements as a vector
C12N 2770/32642 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/32643 viral genome or elements thereof as genetic vector
C12N 2770/32644 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/32645 Special targeting system for viral vectors
C12N 2770/32651	Methods of production or purification of viral material
C12N 2770/32652 relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/32661	Methods of inactivation or attenuation
C12N 2770/32662 by genetic engineering
C12N 2770/32663 by chemical treatment
C12N 2770/32664 by serial passage
C12N 2770/32671	Demonstrated in vivo effect
C12N 2770/32688	For redistribution
C12N 2770/32711	Rhinovirus
C12N 2770/32721	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/32722	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/32723	Virus like particles [VLP]
C12N 2770/32731	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/32732	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/32733	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/32734	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/32741	Use of virus, viral particle or viral elements as a vector
C12N 2770/32742 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/32743 viral genome or elements thereof as genetic vector
C12N 2770/32744 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/32745 Special targeting system for viral vectors

C12N 2770/32751	Methods of production or purification of viral material
C12N 2770/32752	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/32761	Methods of inactivation or attenuation
C12N 2770/32762	by genetic engineering
C12N 2770/32763	by chemical treatment
C12N 2770/32764	by serial passage
C12N 2770/32771	Demonstrated in vivo effect
C12N 2770/32788	For redistribution
C12N 2770/34011	. .	Potyviridae
C12N 2770/34021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/34022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/34023	. . .	Virus like particles [VLP]
C12N 2770/34031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/34032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/34033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/34034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/34041	. . .	Use of virus, viral particle or viral elements as a vector
C12N 2770/34042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/34043	viral genome or elements thereof as genetic vector
C12N 2770/34044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/34045	Special targeting system for viral vectors
C12N 2770/34051	. . .	Methods of production or purification of viral material
C12N 2770/34052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/34061	. . .	Methods of inactivation or attenuation
C12N 2770/34062	by genetic engineering
C12N 2770/34063	by chemical treatment
C12N 2770/34064	by serial passage
C12N 2770/34071	. . .	Demonstrated in vivo effect
C12N 2770/34088	. . .	For redistribution
C12N 2770/36011	. .	Togaviridae
C12N 2770/36021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/36022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/36023	. . .	Virus like particles [VLP]
C12N 2770/36031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/36032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2770/36033	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/36034	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/36041	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2770/36042	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/36043	.	.	.	viral genome or elements thereof as genetic vector
C12N 2770/36044	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/36045	.	.	.	Special targeting system for viral vectors
C12N 2770/36051	.	.	.	Methods of production or purification of viral material
C12N 2770/36052	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/36061	.	.	.	Methods of inactivation or attenuation
C12N 2770/36062	.	.	.	by genetic engineering
C12N 2770/36063	.	.	.	by chemical treatment
C12N 2770/36064	.	.	.	by serial passage
C12N 2770/36071	.	.	.	Demonstrated in vivo effect
C12N 2770/36088	.	.	.	For redistribution
C12N 2770/36111	.	.	.	Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
C12N 2770/36121	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/36122	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/36123	.	.	.	Virus like particles [VLP]
C12N 2770/36131	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/36132	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/36133	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/36134	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/36141	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2770/36142	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/36143	.	.	.	viral genome or elements thereof as genetic vector
C12N 2770/36144	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/36145	.	.	.	Special targeting system for viral vectors
C12N 2770/36151	.	.	.	Methods of production or purification of viral material
C12N 2770/36152	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/36161	.	.	.	Methods of inactivation or attenuation
C12N 2770/36162	.	.	.	by genetic engineering
C12N 2770/36163	.	.	.	by chemical treatment

C12N 2770/36164	by serial passage
C12N 2770/36171	Demonstrated in vivo effect
C12N 2770/36188	For redistribution
C12N 2770/36211	Rubivirus, e.g. rubella virus
C12N 2770/36221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/36222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/36223	Virus like particles [VLP]
C12N 2770/36231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/36232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/36233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/36234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/36241	Use of virus, viral particle or viral elements as a vector
C12N 2770/36242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/36243	viral genome or elements thereof as genetic vector
C12N 2770/36244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/36245	Special targeting system for viral vectors
C12N 2770/36251	Methods of production or purification of viral material
C12N 2770/36252	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/36261	Methods of inactivation or attenuation
C12N 2770/36262	by genetic engineering
C12N 2770/36263	by chemical treatment
C12N 2770/36264	by serial passage
C12N 2770/36271	Demonstrated in vivo effect
C12N 2770/36288	For redistribution
C12N 2770/38011	Tombusviridae
C12N 2770/38021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/38022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/38023	Virus like particles [VLP]
C12N 2770/38031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/38032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/38033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/38034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/38041	Use of virus, viral particle or viral elements as a vector

C12N 2770/38042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/38043	viral genome or elements thereof as genetic vector
C12N 2770/38044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/38045	Special targeting system for viral vectors
C12N 2770/38051	Methods of production or purification of viral material
C12N 2770/38052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/38061	Methods of inactivation or attenuation
C12N 2770/38062	by genetic engineering
C12N 2770/38063	by chemical treatment
C12N 2770/38064	by serial passage
C12N 2770/38071	Demonstrated in vivo effect
C12N 2770/38088	For redistribution
C12N 2770/40011	. . .	Tymoviridae
C12N 2770/40021	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2770/40022	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2770/40023	Virus like particles [VLP]
C12N 2770/40031	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2770/40032	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2770/40033	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2770/40034	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2770/40041	Use of virus, viral particle or viral elements as a vector
C12N 2770/40042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2770/40043	viral genome or elements thereof as genetic vector
C12N 2770/40044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2770/40045	Special targeting system for viral vectors
C12N 2770/40051	Methods of production or purification of viral material
C12N 2770/40052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2770/40061	Methods of inactivation or attenuation
C12N 2770/40062	by genetic engineering
C12N 2770/40063	by chemical treatment
C12N 2770/40064	by serial passage
C12N 2770/40071	Demonstrated in vivo effect
C12N 2770/40088	For redistribution
C12N 2780/00		Naked RNA Viruses (not used)

C12N 2780/00011	. Naked RNA Viruses
C12N 2780/00021	. . Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2780/00022	. . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2780/00023	. . Virus like particles [VLP]
C12N 2780/00031	. . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2780/00032	. . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2780/00033	. . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2780/00034	. . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2780/00041	. . Use of virus, viral particle or viral elements as a vector
C12N 2780/00042	. . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2780/00043	. . . viral genome or elements thereof as genetic vector
C12N 2780/00044	. . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2780/00045	. . . Special targeting system for viral vectors
C12N 2780/00051	. . Methods of production or purification of viral material
C12N 2780/00052	. . . relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2780/00061	. . Methods of inactivation or attenuation
C12N 2780/00062	. . . by genetic engineering
C12N 2780/00063	. . . by chemical treatment
C12N 2780/00064	. . . by serial passage
C12N 2780/00071	. . Demonstrated in vivo effect
C12N 2780/00088	. . For redistribution
C12N 2780/10011	. . Narnaviridae
C12N 2780/10021	. . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2780/10022	. . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2780/10023	. . . Virus like particles [VLP]
C12N 2780/10031	. . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2780/10032	. . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2780/10033	. . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2780/10034	. . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2780/10041	. . . Use of virus, viral particle or viral elements as a vector
C12N 2780/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2780/10043 viral genome or elements thereof as genetic vector
C12N 2780/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2780/10045	Special targeting system for viral vectors
C12N 2780/10051	. . .	Methods of production or purification of viral material
C12N 2780/10052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2780/10061	. . .	Methods of inactivation or attenuation
C12N 2780/10062	by genetic engineering
C12N 2780/10063	by chemical treatment
C12N 2780/10064	by serial passage
C12N 2780/10071	. . .	Demonstrated in vivo effect
C12N 2780/10088	. . .	For redistribution
C12N 2790/00		Viroids and subviral agents (not used)
C12N 2790/00011	. .	Viroids and subviral agents
C12N 2790/00021	. .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2790/00022	. .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2790/00023	. .	Virus like particles [VLP]
C12N 2790/00031	. .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2790/00032	. .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2790/00033	. .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2790/00034	. .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2790/00041	. .	Use of virus, viral particle or viral elements as a vector
C12N 2790/00042	. . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2790/00043	. . .	viral genome or elements thereof as genetic vector
C12N 2790/00044	. . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2790/00045	Special targeting system for viral vectors
C12N 2790/00051	. . .	Methods of production or purification of viral material
C12N 2790/00052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2790/00061	. . .	Methods of inactivation or attenuation
C12N 2790/00062	by genetic engineering
C12N 2790/00063	by chemical treatment
C12N 2790/00064	by serial passage
C12N 2790/00071	. . .	Demonstrated in vivo effect
C12N 2790/00088	. . .	For redistribution
C12N 2790/10011	. .	Prions
C12N 2790/10021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2790/10022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2790/10023	.	.	.	Virus like particles [VLP]
C12N 2790/10031	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2790/10032	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2790/10033	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2790/10034	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2790/10041	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2790/10042	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2790/10043	.	.	.	viral genome or elements thereof as genetic vector
C12N 2790/10044	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2790/10045	.	.	.	Special targeting system for viral vectors
C12N 2790/10051	.	.	.	Methods of production or purification of viral material
C12N 2790/10052	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2790/10061	.	.	.	Methods of inactivation or attenuation
C12N 2790/10062	.	.	.	by genetic engineering
C12N 2790/10063	.	.	.	by chemical treatment
C12N 2790/10064	.	.	.	by serial passage
C12N 2790/10071	.	.	.	Demonstrated in vivo effect
C12N 2790/10088	.	.	.	For redistribution
C12N 2790/12011	.	.		Satellite viruses
C12N 2790/12021	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2790/12022	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2790/12023	.	.	.	Virus like particles [VLP]
C12N 2790/12031	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2790/12032	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2790/12033	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2790/12034	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2790/12041	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2790/12042	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2790/12043	.	.	.	viral genome or elements thereof as genetic vector
C12N 2790/12044	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2790/12045	.	.	.	Special targeting system for viral vectors
C12N 2790/12051	.	.	.	Methods of production or purification of viral material
C12N 2790/12052	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2790/12061	. . .	Methods of inactivation or attenuation
C12N 2790/12062	by genetic engineering
C12N 2790/12063	by chemical treatment
C12N 2790/12064	by serial passage
C12N 2790/12071	. . .	Demonstrated in vivo effect
C12N 2790/12088	. . .	For redistribution
C12N 2790/14011	. .	Viroids
C12N 2790/14021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2790/14022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2790/14023	. . .	Virus like particles [VLP]
C12N 2790/14031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2790/14032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2790/14033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2790/14034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2790/14041	. . .	Use of virus, viral particle or viral elements as a vector
C12N 2790/14042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2790/14043	viral genome or elements thereof as genetic vector
C12N 2790/14044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2790/14045	Special targeting system for viral vectors
C12N 2790/14051	. . .	Methods of production or purification of viral material
C12N 2790/14052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2790/14061	. . .	Methods of inactivation or attenuation
C12N 2790/14062	by genetic engineering
C12N 2790/14063	by chemical treatment
C12N 2790/14064	by serial passage
C12N 2790/14071	. . .	Demonstrated in vivo effect
C12N 2790/14088	. . .	For redistribution
C12N 2792/00		Archaeabacteria viruses (not used)
C12N 2792/00011	. .	Archaeabacteria viruses
C12N 2792/00021	. .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2792/00022	. .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2792/00023	. .	Virus like particles [VLP]
C12N 2792/00031	. .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2792/00032	. .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- C12N 2792/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C12N 2792/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2792/00041 . . Use of virus, viral particle or viral elements as a vector
- C12N 2792/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- C12N 2792/00043 . . . viral genome or elements thereof as genetic vector
- C12N 2792/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- C12N 2792/00045 . . . Special targeting system for viral vectors
- C12N 2792/00051 . . Methods of production or purification of viral material
- C12N 2792/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2792/00061 . . Methods of inactivation or attenuation
- C12N 2792/00062 . . . by genetic engineering
- C12N 2792/00063 . . . by chemical treatment
- C12N 2792/00064 . . . by serial passage
- C12N 2792/00071 . . Demonstrated in vivo effect
- C12N 2792/00088 . . For redistribution
- C12N 2792/10011 . . Fuselloviridae
- C12N 2792/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2792/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2792/10023 . . . Virus like particles [VLP]
- C12N 2792/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- C12N 2792/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2792/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C12N 2792/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2792/10041 . . . Use of virus, viral particle or viral elements as a vector
- C12N 2792/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- C12N 2792/10043 viral genome or elements thereof as genetic vector
- C12N 2792/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- C12N 2792/10045 Special targeting system for viral vectors
- C12N 2792/10051 . . . Methods of production or purification of viral material
- C12N 2792/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2792/10061 . . . Methods of inactivation or attenuation
- C12N 2792/10062 by genetic engineering
- C12N 2792/10063 by chemical treatment

C12N 2792/10064	by serial passage
C12N 2792/10071	. . .	Demonstrated in vivo effect
C12N 2792/10088	. . .	For redistribution
C12N 2792/12011	. .	Guttaviridae
C12N 2792/12021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2792/12022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2792/12023	. . .	Virus like particles [VLP]
C12N 2792/12031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2792/12032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2792/12033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2792/12034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2792/12041	. . .	Use of virus, viral particle or viral elements as a vector
C12N 2792/12042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2792/12043	viral genome or elements thereof as genetic vector
C12N 2792/12044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2792/12045	Special targeting system for viral vectors
C12N 2792/12051	. . .	Methods of production or purification of viral material
C12N 2792/12052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2792/12061	. . .	Methods of inactivation or attenuation
C12N 2792/12062	by genetic engineering
C12N 2792/12063	by chemical treatment
C12N 2792/12064	by serial passage
C12N 2792/12071	. . .	Demonstrated in vivo effect
C12N 2792/12088	. . .	For redistribution

C12N 2795/00 **Bacteriophages (not used)**

C12N 2795/00011	. .	Bacteriophages
C12N 2795/00021	. .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2795/00022	. .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2795/00023	. .	Virus like particles [VLP]
C12N 2795/00031	. .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2795/00032	. .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2795/00033	. .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2795/00034	. .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2795/00041	. .	Use of virus, viral particle or viral elements as a vector

C12N 2795/00042	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2795/00043	.	.	.	viral genome or elements thereof as genetic vector
C12N 2795/00044	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2795/00045	.	.	.	Special targeting system for viral vectors
C12N 2795/00051	.	.	.	Methods of production or purification of viral material
C12N 2795/00052	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2795/00061	.	.	.	Methods of inactivation or attenuation
C12N 2795/00062	.	.	.	by genetic engineering
C12N 2795/00063	.	.	.	by chemical treatment
C12N 2795/00064	.	.	.	by serial passage
C12N 2795/00071	.	.	.	Demonstrated in vivo effect
C12N 2795/00088	.	.	.	For redistribution
C12N 2795/10011	.	.	.	dsDNA Bacteriophages
C12N 2795/10021	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2795/10022	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2795/10023	.	.	.	Virus like particles [VLP]
C12N 2795/10031	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2795/10032	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2795/10033	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2795/10034	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2795/10041	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2795/10042	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2795/10043	.	.	.	viral genome or elements thereof as genetic vector
C12N 2795/10044	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2795/10045	.	.	.	Special targeting system for viral vectors
C12N 2795/10051	.	.	.	Methods of production or purification of viral material
C12N 2795/10052	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2795/10061	.	.	.	Methods of inactivation or attenuation
C12N 2795/10062	.	.	.	by genetic engineering
C12N 2795/10063	.	.	.	by chemical treatment
C12N 2795/10064	.	.	.	by serial passage
C12N 2795/10071	.	.	.	Demonstrated in vivo effect
C12N 2795/10088	.	.	.	For redistribution
C12N 2795/10111	.	.	.	Myoviridae
C12N 2795/10121	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2795/10122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2795/10123	Virus like particles [VLP]
C12N 2795/10131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2795/10132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2795/10133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2795/10134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2795/10141	Use of virus, viral particle or viral elements as a vector
C12N 2795/10142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2795/10143 viral genome or elements thereof as genetic vector
C12N 2795/10144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2795/10145 Special targeting system for viral vectors
C12N 2795/10151	Methods of production or purification of viral material
C12N 2795/10152 relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2795/10161	Methods of inactivation or attenuation
C12N 2795/10162 by genetic engineering
C12N 2795/10163 by chemical treatment
C12N 2795/10164 by serial passage
C12N 2795/10171	Demonstrated in vivo effect
C12N 2795/10188	For redistribution
C12N 2795/10211	Podoviridae
C12N 2795/10221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2795/10222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2795/10223	Virus like particles [VLP]
C12N 2795/10231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2795/10232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2795/10233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2795/10234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2795/10241	Use of virus, viral particle or viral elements as a vector
C12N 2795/10242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2795/10243 viral genome or elements thereof as genetic vector
C12N 2795/10244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2795/10245 Special targeting system for viral vectors

C12N 2795/10251	Methods of production or purification of viral material
C12N 2795/10252	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2795/10261	Methods of inactivation or attenuation
C12N 2795/10262	by genetic engineering
C12N 2795/10263	by chemical treatment
C12N 2795/10264	by serial passage
C12N 2795/10271	Demonstrated in vivo effect
C12N 2795/10288	For redistribution
C12N 2795/10311	. . .	Siphoviridae
C12N 2795/10321	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2795/10322	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2795/10323	Virus like particles [VLP]
C12N 2795/10331	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2795/10332	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2795/10333	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2795/10334	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2795/10341	Use of virus, viral particle or viral elements as a vector
C12N 2795/10342	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2795/10343	viral genome or elements thereof as genetic vector
C12N 2795/10344	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2795/10345	Special targeting system for viral vectors
C12N 2795/10351	Methods of production or purification of viral material
C12N 2795/10352	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2795/10361	Methods of inactivation or attenuation
C12N 2795/10362	by genetic engineering
C12N 2795/10363	by chemical treatment
C12N 2795/10364	by serial passage
C12N 2795/10371	Demonstrated in vivo effect
C12N 2795/10388	For redistribution
C12N 2795/12011	. .	dsRNA Bacteriophages
C12N 2795/12021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2795/12022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2795/12023	. . .	Virus like particles [VLP]
C12N 2795/12031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2795/12032	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2795/12033	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2795/12034	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2795/12041	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2795/12042	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2795/12043	.	.	.	viral genome or elements thereof as genetic vector
C12N 2795/12044	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2795/12045	.	.	.	Special targeting system for viral vectors
C12N 2795/12051	.	.	.	Methods of production or purification of viral material
C12N 2795/12052	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2795/12061	.	.	.	Methods of inactivation or attenuation
C12N 2795/12062	.	.	.	by genetic engineering
C12N 2795/12063	.	.	.	by chemical treatment
C12N 2795/12064	.	.	.	by serial passage
C12N 2795/12071	.	.	.	Demonstrated in vivo effect
C12N 2795/12088	.	.	.	For redistribution
C12N 2795/14011	.	.		ssDNA Bacteriophages
C12N 2795/14021	.	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2795/14022	.	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2795/14023	.	.	.	Virus like particles [VLP]
C12N 2795/14031	.	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2795/14032	.	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2795/14033	.	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2795/14034	.	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2795/14041	.	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2795/14042	.	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2795/14043	.	.	.	viral genome or elements thereof as genetic vector
C12N 2795/14044	.	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2795/14045	.	.	.	Special targeting system for viral vectors
C12N 2795/14051	.	.	.	Methods of production or purification of viral material
C12N 2795/14052	.	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2795/14061	.	.	.	Methods of inactivation or attenuation
C12N 2795/14062	.	.	.	by genetic engineering

C12N 2795/14063	by chemical treatment
C12N 2795/14064	by serial passage
C12N 2795/14071	Demonstrated in vivo effect
C12N 2795/14088	For redistribution
C12N 2795/14111	Inoviridae
C12N 2795/14121	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2795/14122	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2795/14123	Virus like particles [VLP]
C12N 2795/14131	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2795/14132	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2795/14133	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2795/14134	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2795/14141	Use of virus, viral particle or viral elements as a vector
C12N 2795/14142	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2795/14143	viral genome or elements thereof as genetic vector
C12N 2795/14144	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2795/14145	Special targeting system for viral vectors
C12N 2795/14151	Methods of production or purification of viral material
C12N 2795/14152	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2795/14161	Methods of inactivation or attenuation
C12N 2795/14162	by genetic engineering
C12N 2795/14163	by chemical treatment
C12N 2795/14164	by serial passage
C12N 2795/14171	Demonstrated in vivo effect
C12N 2795/14188	For redistribution
C12N 2795/14211	Microviridae
C12N 2795/14221	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2795/14222	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2795/14223	Virus like particles [VLP]
C12N 2795/14231	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2795/14232	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2795/14233	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2795/14234	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2795/14241	Use of virus, viral particle or viral elements as a vector
C12N 2795/14242	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2795/14243	viral genome or elements thereof as genetic vector
C12N 2795/14244	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2795/14245	Special targeting system for viral vectors
C12N 2795/14251	Methods of production or purification of viral material
C12N 2795/14252	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2795/14261	Methods of inactivation or attenuation
C12N 2795/14262	by genetic engineering
C12N 2795/14263	by chemical treatment
C12N 2795/14264	by serial passage
C12N 2795/14271	Demonstrated in vivo effect
C12N 2795/14288	For redistribution
C12N 2795/16011	. .	ssRNA Bacteriophages negative-sense
C12N 2795/16021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2795/16022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2795/16023	. . .	Virus like particles [VLP]
C12N 2795/16031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2795/16032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2795/16033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2795/16034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2795/16041	. . .	Use of virus, viral particle or viral elements as a vector
C12N 2795/16042	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2795/16043	viral genome or elements thereof as genetic vector
C12N 2795/16044	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2795/16045	Special targeting system for viral vectors
C12N 2795/16051	Methods of production or purification of viral material
C12N 2795/16052	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2795/16061	Methods of inactivation or attenuation
C12N 2795/16062	by genetic engineering
C12N 2795/16063	by chemical treatment
C12N 2795/16064	by serial passage
C12N 2795/16071	Demonstrated in vivo effect
C12N 2795/16088	For redistribution

C12N 2795/18011	.	.	ssRNA Bacteriophages positive-sense
C12N 2795/18021	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2795/18022	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2795/18023	.	.	Virus like particles [VLP]
C12N 2795/18031	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2795/18032	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2795/18033	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2795/18034	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2795/18041	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2795/18042	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2795/18043	.	.	viral genome or elements thereof as genetic vector
C12N 2795/18044	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N 2795/18045	.	.	Special targeting system for viral vectors
C12N 2795/18051	.	.	Methods of production or purification of viral material
C12N 2795/18052	.	.	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2795/18061	.	.	Methods of inactivation or attenuation
C12N 2795/18062	.	.	by genetic engineering
C12N 2795/18063	.	.	by chemical treatment
C12N 2795/18064	.	.	by serial passage
C12N 2795/18071	.	.	Demonstrated in vivo effect
C12N 2795/18088	.	.	For redistribution
C12N 2795/18111	.	.	Leviviridae
C12N 2795/18121	.	.	Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2795/18122	.	.	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N 2795/18123	.	.	Virus like particles [VLP]
C12N 2795/18131	.	.	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
C12N 2795/18132	.	.	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2795/18133	.	.	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 2795/18134	.	.	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2795/18141	.	.	Use of virus, viral particle or viral elements as a vector
C12N 2795/18142	.	.	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N 2795/18143	.	.	viral genome or elements thereof as genetic vector
C12N 2795/18144	.	.	Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2795/18145	Special targeting system for viral vectors
C12N 2795/18151	Methods of production or purification of viral material
C12N 2795/18152	relating to complementing cells and packaging systems for producing virus or viral particles
C12N 2795/18161	Methods of inactivation or attenuation
C12N 2795/18162	by genetic engineering
C12N 2795/18163	by chemical treatment
C12N 2795/18164	by serial passage
C12N 2795/18171	Demonstrated in vivo effect
C12N 2795/18188	For redistribution

C12N 2799/00 **Uses of viruses**

WARNING

From March 15, 2012 codes in the range [C12N 2799/00](#) - [C12N 2799/06](#) are no longer used for the classification of new documents. The documents in this range are being reclassified to the corresponding codes in [C12N 2710/00-C12N 2795/00](#)

C12N 2799/02	. . .	as vector
C12N 2799/021	. . .	for the expression of a heterologous nucleic acid
C12N 2799/022	. . .	where the vector is derived from an adenovirus
C12N 2799/023	. . .	where the vector is derived from a poxvirus
C12N 2799/025	. . .	where the vector is derived from a parvovirus
C12N 2799/026	. . .	where the vector is derived from a baculovirus
C12N 2799/027	. . .	where the vector is derived from a retrovirus
C12N 2799/028	. . .	where the vector is derived from a herpesvirus
C12N 2799/04	. . .	in vivo
C12N 2799/06	. . .	in vitro

C12N 2800/00 **Nucleic acids vectors**

C12N 2800/10	. . .	Plasmid DNA
C12N 2800/101	. . .	for bacteria
C12N 2800/102	. . .	for yeast
C12N 2800/103	. . .	for invertebrates
C12N 2800/105	. . .	for insects
C12N 2800/106	. . .	for vertebrates
C12N 2800/107	. . .	for mammalian
C12N 2800/108	. . .	episomal vectors
C12N 2800/20	. . .	Pseudochromosomes, minichromosomes
C12N 2800/202	. . .	of bacteriophage origin
C12N 2800/204	. . .	of bacterial origin, e.g. BAC

C12N 2800/206	. . of yeast origin, e.g. YAC, 2u
C12N 2800/208	. . of mammalian origin, e.g. minichromosome
C12N 2800/22	. Vectors comprising a coding region that has been codon optimised for expression in a respective host
C12N 2800/24	. Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
C12N 2800/30	. Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
C12N 2800/40	. Systems of functionally co-operating vectors
C12N 2800/50	. Vectors for producing vectors
C12N 2800/60	. Vectors containing traps for, e.g. exons, promoters
C12N 2800/70	. Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites
C12N 2800/80	. Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
C12N 2800/90	. Vectors containing a transposable element
C12N 2800/95	. Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers
C12N 2810/00	Vectors comprising a targeting moiety
C12N 2810/10	. Vectors comprising a non-peptidic targeting moiety
C12N 2810/40	. Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
C12N 2810/405	. . Vectors comprising RGD peptide
C12N 2810/50	. Vectors comprising as targeting moiety peptide derived from defined protein
C12N 2810/55	. . from bacteria
C12N 2810/60	. . from viruses
C12N 2810/6009	. . . dsDNA viruses
C12N 2810/6018 Adenoviridae
C12N 2810/6027	. . . ssDNA viruses
C12N 2810/6036	. . . DNA rev transcr viruses
C12N 2810/6045	. . . RNA rev transcr viruses
C12N 2810/6054 Retroviridae
C12N 2810/6063	. . . ds RNA viruses
C12N 2810/6072	. . . negative strand RNA viruses
C12N 2810/6081 rhabdoviridae, e.g. VSV
C12N 2810/609	. . . positive strand RNA viruses
C12N 2810/65	. . from plants
C12N 2810/70	. . from fungi
C12N 2810/75	. . from invertebrates
C12N 2810/80	. . from vertebrates
C12N 2810/85	. . . mammalian
C12N 2810/851 from growth factors; from growth regulators

C12N 2810/852 from cytokines; from lymphokines; from interferons
C12N 2810/853 from tumor necrosis factor, TNF
C12N 2810/854 from hormones
C12N 2810/855 from receptors; from cell surface antigens; from cell surface determinants
C12N 2810/856 from integrins
C12N 2810/857 from blood coagulation or fibrinolysis factors
C12N 2810/858 from apolipopptides
C12N 2810/859 from immunoglobulins
C12N 2810/90	. . . avian

C12N 2820/00**Vectors comprising a special origin of replication system**

C12N 2820/002	. inducible or controllable
C12N 2820/005	. cell-cycle regulated
C12N 2820/007	. tissue or cell-specific
C12N 2820/10	. multiple origins of replication
C12N 2820/55	. from bacteria
C12N 2820/60	. from viruses
C12N 2820/65	. from plants
C12N 2820/70	. from fungi
C12N 2820/702	. . yeast
C12N 2820/704	. . . S. cerevisiae
C12N 2820/706	. . . S. pombe
C12N 2820/708	. . . C. albicans
C12N 2820/75	. from invertebrates
C12N 2820/80	. from vertebrates
C12N 2820/85	. . mammalian
C12N 2820/90	. . avian

C12N 2830/00**Vector systems having a special element relevant for transcription**

C12N 2830/001	. controllable enhancer/promoter combination
C12N 2830/002	. . inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
C12N 2830/003	. . . tet inducible
C12N 2830/005	. . repressible enhancer/promoter combination, e.g. KRAB
C12N 2830/006	. . . tet repressible
C12N 2830/007	. cell cycle specific enhancer/promoter combination
C12N 2830/008	. cell type or tissue specific enhancer/promoter combination
C12N 2830/15	. chimeric enhancer/promoter combination
C12N 2830/20	. transcription of more than one cistron
C12N 2830/205	. . bidirectional
C12N 2830/30	. being an enhancer not forming part of the promoter region
C12N 2830/32	. being an silencer not forming part of the promoter region

- C12N 2830/34 . being a transcription initiation element
- C12N 2830/36 . being a transcription termination element
- C12N 2830/38 . being a stuffer
- C12N 2830/40 . being an insulator
- C12N 2830/42 . being an intron or intervening sequence for splicing and/or stability of RNA
- C12N 2830/46 . elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
- C12N 2830/48 . regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- C12N 2830/50 . regulating RNA stability, not being an intron, e.g. poly A signal
- C12N 2830/52 . encoding ribozyme for self-inactivation
- C12N 2830/55 . from bacteria
- C12N 2830/60 . from viruses
- C12N 2830/65 . from plants
- C12N 2830/70 . from fungi
- C12N 2830/702 . . yeast
- C12N 2830/704 . . . *S. cerevisiae*
- C12N 2830/706 . . . *S. pombe*
- C12N 2830/708 . . . *C. albicans*
- C12N 2830/75 . from invertebrates
- C12N 2830/80 . from vertebrates
- C12N 2830/85 . . mammalian
- C12N 2830/90 . . avian

C12N 2840/00**Vectors comprising a special translation-regulating system**

- C12N 2840/002 . controllable or inducible
- C12N 2840/005 . cell cycle specific
- C12N 2840/007 . cell or tissue specific
- C12N 2840/10 . regulates levels of translation
- C12N 2840/102 . . inhibiting translation
- C12N 2840/105 . . enhancing translation
- C12N 2840/107 . . inhibiting translational read-through
- C12N 2840/20 . translation of more than one cistron
- C12N 2840/203 . . having an IRES
- C12N 2840/206 . . . having multiple IRES
- C12N 2840/44 . being a specific part of the splice mechanism, e.g. donor, acceptor
- C12N 2840/445 . . for trans-splicing, e.g. polypyrimidine tract, branch point splicing
- C12N 2840/50 . utilisation of non-ATG initiation codon

NOTE

C12N 2840/50

(continued)

This groups covers artificial modification only, i.e. naturally occurring use of non-ATG start codon is not classified here

- C12N 2840/55 . from bacteria
- C12N 2840/60 . from viruses
- C12N 2840/65 . from plants
- C12N 2840/70 . from fungi
- C12N 2840/702 . . yeast
- C12N 2840/704 . . . S. cerevisiae
- C12N 2840/706 . . . S. pombe
- C12N 2840/708 . . . C. albicans
- C12N 2840/75 . from invertebrates
- C12N 2840/80 . from vertebrates
- C12N 2840/85 . . mammalian
- C12N 2840/90 . . avian

C12N 2999/00

Further aspects of viruses or vectors not covered by the [C12N 2700/00](#) or [C12N 2800/00](#) series

NOTES

1. This group is for classification of patent and non-patent literature documents.
2. When classifying non-patent literature in this group, classification must also be given for the relevant CPC groups, to define the technical area to which they relate.

- C12N 2999/002 . Adverse teaching
- C12N 2999/005 . Biological teaching, e.g. a link between protein and disease, new virus causing pandemic
- C12N 2999/007 . Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals